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Abstract:
Development of CXCR4-inhibiting gene delivery vectors for the treatment of
metastatic pancreatic cancer
Yu Hang, Ph.D.
University of Nebraska Medical Center, 2020
Supervisor: David Oupický, Ph.D.
Pancreatic ductal adenocarcinoma (PDAC) is a growing medical problem
associated with extensive metastasis and high mortality. Late diagnosis and complexity
of the tumor microenvironment (TME) with severe hypoxia, desmoplasia, and
hypovascular nature contributes to poor effectiveness of conventional chemotherapies.
RNA interference (RNAi) holds great potential in the treatment of multiple genetic and
acquired diseases, including PDAC. CXCR4/CXCL12 chemokine axis plays a pivotal
role in PDAC TME remodeling to promote tumor proliferation, angiogenesis,
metastasis, and chemoresistance. This project developed polymeric AMD3100 (PAMD)
derivatives as dual-function vectors capable of simultaneously delivering small RNAs
and blocking CXCR4/CXCL12 signaling.
Administration route plays pivotal role in determining the fate of therapeutics in
the body. This project first compared intravenous (IV) and intraperitoneal (IP)
administration of the developed nanoparticles (PAMD-CHOL/siRNA) in a murine
orthotopic PDAC model. IP administration greatly improved tumor accumulation by
providing high local concentrations and prolonged residence time of the particles in the
peritoneal cavity, while the efficiency of IV administration was severely compromised

in part due to hypovascularity and dense desmoplastic stroma.
Triple combination therapy using PAMD-CHOL nanoparticles consisting of antimiR-210 and siKRASG12D displayed improved therapeutic effect in the treatment of
PDAC when compared with individual therapies as documented by delayed tumor
growth, depletion of stroma, reduction of immunosuppression, inhibition of metastasis,
and prolonged survival.
To further understand how physiochemical properties of the nanoparticles
contribute to enhanced tumor accumulation, this project developed five formulations
with

different

surface

properties.

Positively

charged

mPAMD-TFTA/siRNA

nanoparticles displayed the highest tumor accumulation at 24 h after IP administration
in orthotopic PDAC mice. Treatment of mPAMD-TFTA/siPLK1 nanoparticles with
combination of CXCR4 inhibition and PLK1 downregulation in PDAC mice showed
significant inhibition of both primary and metastatic tumors.
Overall, the studies demonstrated the benefits of local IP delivery for the
treatment of PDAC. Our data provide insights into and guides the design of the
nanoparticles for improved drug delivery in PDAC by IP administration.
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Chapter 1. Introduction
1.1. Pancreas anatomy and functions
Pancreas is the organ located behind the stomach in the upper left portion of the
abdomen that functions as a gland. Human pancreas weighs about 100 grams with
the length of 14-20 centimeters [1]. It is divided into four portions as head, neck, body
and tail (Figure 1.1A). The head of the pancreas lies along the curvature of the
duodenum. The neck separates the head and body of the pancreas and is in proximity
to some main blood vessels, including superior mesenteric artery, superior mesentericportal vein, inferior vena cava, and aorta. The body, as the largest part of the pancreas,
stretches posterior to the stomach and narrows into the tail which sits near the hilum
of the spleen.
Pancreas consists of acinar cells, duct cells, and islets of Langerhans (Figure
1.1B). It functions both as an exocrine and an endocrine gland. 95% of pancreas is
composed of exocrine cells including duct and acinar cells that can produce zymogens
into the gastrointestinal tract for food digestion. The acinar cells are organized as
functional units along the duct network with centroacinar cells located at the junction
(Figure 1.1C) [2]. The synthesized zymogens are released from acinar cells and joining
into a bicarbonate-rich solution secreted by the centroacinar and ductal cells and flows
through the branch ducts into the main pancreatic duct [1]. The pancreatic juices
combined in the main duct with the digestive bile produced from the gallbladder are
released into the duodenum, the first portion of the small intestine, in response to cues
to help the body digest fats, carbohydrates, and proteins. The remaining tissue that
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works as an endocrine consists of cells called islets of Langerhans, which are located
throughout the pancreas. Instead of releasing the secretions into the ducts, the islets
release hormones, such as insulin and glucagon directly into the bloodstream to help
regulate metabolism and maintain glucose homeostasis [3]. Islets consist of three
major hormone-secreting cell types, including β cells, α cells, δ cells and several other
types. The composition of the islet varies between species and even within species
under different physiological conditions [4]. β cells, as the most studied islet cell types,
produce insulin which can facilitate the uptake of glucose by cells (particularly skeletal
muscle) as blood glucose levels rise, while α cells produce the hormone glucagon to
increase the release of glucose from liver to blood when blood-glucose levels decline.
δ cells can secrete somatostatin, a negative regulator of insulin, glucagon and other
pancreatic hormones under stimulating conditions [5]. Islets are highly vascularized,
allowing secretion of hormones readily into the blood circulation. They are also
innervated by sympathetic and parasympathetic neurons to modulate the secretion of
insulin and glucagon with nervous signals [6].
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Figure 1.1. Anatomy of the pancreas. (A) Gross anatomy of the pancreas. (B) The
major components of the pancreas on a histological level. (C) Representation of
acinar unit with the relationship to pancreatic ducts (Adapted from [2]).

1.2. Pancreatic cancer
Pancreatic cancer is one of the most lethal types of cancer among men and
women, with the overall 5-year survival rate of around 9% [7]. In 2020, it is estimated
that 57,600 people will be diagnosed with pancreatic cancer, and approximately 47,050
people will die from this disease in the United States [7]. The incidence and death rate
of pancreatic cancer have been continuously increasing over the recent decades [8],
while the death rate for most other cancers have been stable or decreasing [9]. About
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10% of the pancreatic cancers are inherited as germ-line mutations passed from one
generation to the next [10], while the other 90% are considered somatic mutations.
There are some factors that may increase the risk of developing pancreatic cancer. In
fact, 90% of the patients with pancreatic cancer are older than 55 years old, with men
represented slightly more than women. The risk also increases in African Americans
or people with family histories of the disease. There are other risk factors that are
preventable, such as tobacco use, obesity, alcohol use-related chronic pancreatitis,
and exposure to certain chemicals [11, 12]. Pancreatic cancers have different types.
Based on the cell of origin, pancreatic ductal adenocarcinoma (PDAC) is the most
common type (~90%) developed from pancreatic duct cells characterized by atypical
neoplastic glands in dense stroma. The next most frequently developed are the
pancreatic neuroendocrine tumors (PNETs) arising from the endocrine pancreas,
which result in the hormone release abnormalities. However, PNETs tend to grow more
slowly and have a much better prognosis than PDAC. Other rare exocrine cancers
include

acinar

cell

carcinoma,

solid

pseudopapillary

neoplasm,

and

pancreatoblastoma [13, 14]. This dissertation will mainly focus on the discussion and
research regarding PDAC.
1.2.1. PDAC precursor lesions
PDAC develops from three main precursor lesions: pancreatic intraepithelial
neoplasia (PanIN), intraductal papillary mucinous neoplasm (IPMN) and mucinous
cystic neoplasm (MCN). These precursor lesions may be used as a prediction of
potential PDAC and present as an opportunity to increase the survival rate by
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diagnosing and treating PDAC at early stages.
1.2.1.1. Pancreatic intraepithelial neoplasia (PanIN)
Majority of the PDACs are believed to be developed from PanIN, which is the
microscopic flat or capillary noninvasive precursor lesion typically arising within the
smaller-caliber pancreatic ducts. PanINs are graded from stage I to III with increasing
architectural and nuclear dysplasia [15]. PanIN-1A and PanIN-1B are the lowest grade
lesions with minimal dysplasia compared to the normal ducts with differences in flat or
micropapillary infoldings of the epithelium. PanIN-2 is associated with moderate
degree of dysplasia with papillary epithelium and cytological atypia, including nuclear
crowing, enlarged nuclei, and hyperchromatism. PanIN-3 is considered a high-grade
dysplasia, also known as carcinoma in situ, with substantial papillary epithelium,
severe degree of cytological atypia [16] and atypical mitoses, but still within the
basement membrane.
Apart from the histological progression from PanIN-1 to PanIN-3, accumulated
genetic alternations are also present. The PanIN are invasive PDAC precursors
supported by the commonalities they share at the genetic level. KRAS oncogene
mutations are the earliest and the most common genetic alterations in PanINs with
increasing mutant allele frequency from PanIN-1 to PanIN-3. They are found in more
than 90% of the PDAC cases [17]. The most frequent mutation point is at the codon
12 in KRAS gene, which is considered as the driver for the PDAC formation [2, 15, 18].
These mutations on KRAS generate a constitutively active RAS, which is involved in
signal transduction and hyperstimulation of the downstream cascades including RAF-
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MEK-ERK and PI3K/PDK1/AKT signaling networks driving hallmarks of cancer [19,
20]. Telomere shortening is another common early event occurring in PanIN compared
with normal ductal epithelium. The shortened telomeres will not be effectively working
to prevent fusion between ends of the chromosomes during cell division, leading to
chromosome instability and finally pave the way for neoplastic progression in cells [21,
22]. The inactivation of the tumor suppressor genes, including CDKN2A/p16, TP53,
and SMAD4/DPC4 is highly prevalent in invasive PDAC (50-80%) [23] and also
presented in PanIN lesions. These mutations, which appear to occur after oncogenic
KRAS mutation and telomere shortening, drive neoplastic progression in PanIN lesions
[24-26]. CDNK2A/p16 gene is located at chromosome 9q21 which inhibits G1/S cell
cycle transition. Inactivation of CDKN2A/p16 is detected in the early PanIN stages and
becomes more frequent with increasing PanIN grades (30% of PanIN-1, 55% of PanIN2 and 70% of PanIN-3 [16]), suggesting that the loss of p16 is required for the
progression rather than initiation of PanIN. The inactivation of TP53 and SMAD4 are
typically seen in advanced-grade lesions (mainly found in 30-50% PanIN-3 [16]). TP53
gene located at chromosome 17p13.1 encodes for p53 protein which is involved in the
maintenance of G2/M cell cycle arrest and the induction of apoptosis. Loss of p53 will
result in the irregular cell division and cell death. The SMAD4/DPC4 gene located at
chromosome 18q21.1 plays an important role in the transforming growth factor β (TGFβ) signaling pathway. Loss of SMAD4 leads to decreased growth inhibition and support
of the proliferation of the cancer cells [27]. In addition to genetic alterations, epigenetic
changes can also promote the progression of PanIN. Aberrant hypermethylation of
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gene promoters is the predominant epigenetic change that can lead to gene silencing
[28]. These accumulated genetic and epigenetic alterations may eventually lead to the
progression of invasive PDAC formation.
1.2.1.2. Intraductal papillary mucinous neoplasm (IPMN)
IPMNs are premalignant cystic epithelial neoplasms with papillary projections and
mucin production, predominantly present in the head of the pancreas. While PanINs
are microscopic lesions, IPMNs are grossly detectable masses with sizes larger than
5 mm and involve the main or branches of the pancreatic ducts. Based on the location,
IPMNs can be categorized into main duct (MD), branch duct (BD) and mixed types.
Compared with the BD-type, the MD and mixed-type IPMNs are usually associated
with higher grade dysplasia and higher chances of invasive carcinomas (40-50% for
MD or mixed types, lower than 20% for BD type) [29]. Based on histopathologic
features, IPMN can be classified into four subtypes, including gastric, intestinal,
pancreatobiliary and oncocytic types. Gastric-type IPMNs are the lesions with basally
located small nuclei and abundant apical cytoplasmic mucin [24]. They usually
communicate with the BD and tend to have low-grade dysplasia. Pancreatoniliary-type
IPMNs have more complex architecture with branched papillae and are frequently
observed in MD. The neoplastic cells are generally cuboidal with rounded atypical
nuclei [30]. They are typically associated with high-grade lesions and tend to be classic
tubular-type ductal adenocarcinoma if developed into invasive carcinomas [31].
Intestinal-type IPMNs consist of long finger-like projections lined by tall columnar
mucin-producing neoplastic cells with elongated nuclei [30]. They commonly involve
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the MD and have moderate to severe dysplasia [32]. Associated invasive carcinomas
arising from this type of IPMNs are colloid carcinomas with abundant extracellular
mucins [33]. Oncocytic-type IPMNs are the rare variants characterized by oncocytic
cells with intricate arborizing papillae, cribriform architectures and solid nests [17, 34].
The tumor cells have eosinophilic cytoplasm with large nuclei and plenty of
mitochondria. Oncocytic-type IPMNs are mainly found in the pancreatic MD and
observed with high-grade dysplasia or carcinoma in situ. They will convert into the
infrequent oncocytic carcinoma when becoming invasive [27]. These subtypes do not
present completely distinct as many IPMNs show mixed histologic features.
IPMNs have many shared genetic mutations described in invasive PDAC as well
as some distinct genetic abnormities. Highly mutated genes in PDAC including KRAS,
CDKN2A/p16, TP53 and SMAD are also found in IPMNs but with lower reported
frequency [18, 23, 35]. The gene mutation frequencies increase along with the
increasing grade of dysplasia. There are some more selectively altered genes that
exclusively present in IPMNs than other precursor lesions or PDAC. GNAS is a key
oncogene mutated more common and specific in IPMNs (40-80%), especially in
intestinal-type IPMNs [36-38]. Inactivation of the Peutz-Jeghers syndrome gene
STK11/LKB1 has be reported in about 25% of the sporadic IPMNs [39]. PIK3CA, an
oncogene associated with the AKT signaling pathway is found activated in about 10%
intermediate to high-grade IPMNs [40].
1.2.1.3. Mucinous cystic neoplasm (MCN)
MCNs are mucin-producing epithelial cystic lesions mostly detected in body and
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tail of the pancreas. They present as relatively rare types of precursor lesions that
can give rise to invasive PDAC and arise predominantly in women (90%). MCNs
show unilocular to multilocular epithelial cysts lined by cuboidal to columnar mucinsecreting neoplastic epithelium cells surrounded by ovarian-type stroma [17, 41]. In
contrast to IPMNs, MCNs usually show no communication with the main pancreatic
duct system. With varying degree of cytological and architectural atypia, MCNs can
be classified from low to high grades as mucinous cystadenomas, MCN with
moderate dysplasia and MCN with carcinoma in situ. Majority of the MCNs are lowgrade with good prognosis after surgical resection. About 15% of the MCNs are
associated with invasive carcinoma with 5-year survival rate of 50-60% [16, 42]. The
genetic alterations underlying MCN formation and progression overlapped with those
in PanIN, IPMN and PDAC. The most frequently mutated gene is again KRAS which
is detected early in low-grade MCNs and increased mutation frequencies are found in
advanced cases [43]. Mutations of TP53 and SMAD4/DPC4 are relatively late events
mainly observed in high-grade MCNs and invasive carcinomas [15, 41].
1.2.2. PDAC diagnosis, staging and treatment options
The key to improving prognosis of PDAC is the detection of smaller and earlier
stage lesions. However, how asymptomatic the early stage PDAC is, most of the
patients are diagnosed at late stage when the disease became locally advanced or
even metastasized to distant organs with appearance of clinical presentations like
abdominal pain, weight loss, nausea and jaundice. The late diagnosis makes
approximately 80-90% of the patients ineligible for resection surgery [44, 45]. The
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increasing incidence and extremely low survival rate of PDAC make it urgent enough
to consider screening, especially in high risk individuals. Unfortunately, there are no
biomarkers with high accuracy currently available [46].
1.2.2.1. PDAC diagnosis
The most important tool for diagnosis of PDAC is imaging. For patients presenting
with common symptoms of PDAC, transabdominal ultrasound is usually the
reasonable first imaging method for initial screening as it is noninvasive and
inexpensive. However, it lacks sensitivity especially for small tumors (less than 3 cm)
[47]. Computed tomography (CT) scans including multi-detectors, intravenous contrast,
curved planner reformations and CT angiography are the most widely used, bestvalidated imaging modality for PDAC diagnosis and staging [48]. Multi-detector CT
shows up to 90% effectiveness at predicting the resectability of the PDAC tumor mass
[49]. The magnetic resonance imaging (MRI) can be performed as an adjunct to CT to
better define the tumor mass with its high resolution for small tumors and to predict
resectability. Another imaging tool that can be used in combination with CT is
endoscopic ultrasound with the sensitivity of 97% [50] for small tumors. It provides
high-resolution imaging of associated vascular structures and allows evaluation of
lymph node involvement. The combination of positron emission tomography (PET) with
fluorine-18 fluorodeoxyglucose and high-end multi-detector CT is more sensitive than
conventional imaging and can be used for the detection of hepatic metastasis and
monitoring cancer progression following treatment. These imaging methods have very
important roles in early and accurate diagnosis of PDAC for helping doctors choose
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effective and timely treatment options for patients.
1.2.2.2. PDAC staging
Based on the diagnostic imaging, patients can be classified into different PDAC
stages for stage-specific treatment and prognosis. The most widely accepted staging
system is the TNM system maintained by the American Joint Committee on Cancer
(AJCC) [51]. This staging system consists of an assessment of the primary tumor,
lymph nodes and metastasis (Table 1.1) and their combination to determine the stage
of the disease (Table 1.2). The earliest stage of PDAC is stage 0, and then goes from
stage I to stage IV based on the primary tumor size (T stage), numbers of regional
lymph nodes metastasis (N stage) and distant metastasis (M stage). The resectability
of the tumor is only limited to stages prior to stage III with further consideration of its
location in the pancreas and involvement of local arteries and veins. Most of the PDAC
patients are diagnosed at late stages with five-year survival rate decreasing
dramatically. Further studies with detection of other prognostic markers including
serum liver enzyme tests, tumor marker levels (CA 19-9, CEA, MIC-1, etc.) [47],
circulating tumor cells [52], cell-free DNA and integrated pathway subtypes may better
help guide the treatment of PDAC patients at all stages.
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Table 1.1. Tumor, node, metastasis classification of PDAC (Adapted from [53]).
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Table 1.2. TNM staging classification of PDAC with diagnosis and five-year survival
rate [53, 54].

1.2.2.3. PDAC treatment options
Surgical resection is the only curative treatment for PDAC, yet only 15-20% of the
patients are in early stages with resectable lesions. Even in this subset of patients, the
primary or metastatic tumors may recur months to years after surgery and the five-year
survival rate is still lower than 20% [54, 55]. Pancreaticoduodenectomy is the classic
surgery for resection of the tumors in the head of the pancreas and distal
pancreatectomy with or without splenectomy is typically used for tumors involving the
body or tail of the pancreas. The use of adjuvant chemotherapy post-resection has
demonstrated a survival benefit for patients and is now widely used as a standard of
care [56, 57]. Chemotherapy with gemcitabine or fluorouracil/leucovorin are used and
may also be combined with adjuvant radiation therapy. Surveillance of cancer
recurrence is recommended for patients to have physical examination every three to
six months for two years, then annually [58]. Some studies have addressed the use of
chemoradiation with chemotherapy to downstage the borderline resectable disease to
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resectable status. Patients benefit from the treatments and have similar survival rate
with those initially resectable cases.
For advanced pancreatic cancer patients, systemic chemotherapy followed by
consolidation chemoradiation therapy is a recommend treatment option from the
National Comprehensive Cancer Network (NCCN). Gemcitabine is a standard of firstline chemotherapy for the treatment of PDAC, yet it can only extend the median
survival by about 1.5 months [59] and the response rate is disappointingly low. Clinical
trials of novel regimens have been conducted with comparison of gemcitabine
monotherapy. FOLFIRINOX, a combination of oxaliplatin, 5-fluorouracil, leucovorin
and irinotecan showed significantly increased survival outcomes and improved
response rate compared to gemcitabine treatment [60, 61]. However, the adverse
effects associated with FOLFIRINOX are more severe than gemcitabine and the
treatment is only recommend for younger patients with good performance status [45].
Additionally, gemcitabine with albumin nanoparticle-bound paclitaxel (nab-paclitaxel)
combination also demonstrated superiority over gemcitabine monotherapy for the
treatment of metastatic PDAC [62, 63]. This regimen can be used in a wider range of
patients compared to FOLFIRINOX as the adverse effects seem to be more
manageable [45], but still increased compared to gemcitabine alone. Recent
innovation in radiation therapy can allow an increase of the target dose to the tumor
sites while sparing radiation to nearby healthy tissues [64]. It can be used in
combination with the chemotherapy but the survival benefits of chemoradiation therapy
are still debated [45, 65]. Palliative care for patients with locally advanced and
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metastatic PDAC should address symptoms from biliary and duodenal obstruction,
cancer-related pain, malnutrition, and depression. Some of them can be relieved by
surgical, endoscopic, or radiological techniques and adjusting the treatment.
Although the FOLFIRINOX cocktail therapy and gemcitabine with nab-paclitaxel
combination provide some improvements in efficacy and survival, the toxicity and drug
resistance limit the number of targeted patients. Effective treatment options for PDAC
patients are still very limited. Thus, there is an urgent need to develop new therapeutic
strategies for the treatment of PDAC, as well as to find an appropriate administration
route to increase drug concentrations and retention time in the tumor sites.
1.2.3. Pancreatic cancer microenvironment
The obstacles to effective treatment for pancreatic cancer may in part be
explained by the diverse tumor microenvironment (TME). PDAC microenvironment
consists of various components in a constantly changing status (Scheme 1.1). These
components can interact with each other and facilitate desmoplasia and
immunosuppression in both primary and metastatic sites, contributing to the dismal
prognosis of patients. New therapeutic approaches by modulating the TME might be
promising strategies for effective PDAC therapy.
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Scheme 1.1. Components of tumor microenvironment in pancreatic cancer (Adapted
from [66]).

1.2.3.1. PDAC stroma
Pancreatic cancer is one of the most stroma-rich cancers, with around 80% of
the tumor components as dense stroma and only 10-30% as cancer cells [67]. The
stroma is very heterogeneous and consists of cellular and noncellular components
including fibroblasts, myofibroblasts, pancreatic stellate cells (PSCs), immune cells,
blood vessels, extracellular matrix (ECM), cytokines and growth factors.
PSCs are a subset of cancer-associated fibroblasts (CAFs), which are the
principal source of the excessive desmoplasia. These cells interact closely with
cancer cells to create a pro-tumorigenic environment. Under acute or chronic
inflammatory conditions, PSCs can be activated from their quiescent status by
factors such as interleukin-1 (IL-1), IL-6, tumor necrosis factor α (TNF-α) and TGF-β
[68-70]. When activated, PSCs switch to a myofibroblast phenotype, which leads to
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their increased proliferation, secretion of matrix metalloproteinases (MMPs), MMP
inhibitors and ECM proteins, expression of α-smooth muscle actin (α-SMA) as well
as loss of cytoplasmic fat droplets [71, 72]. Activated PSCs can in turn produce
autocrine factors such as TGFβ, platelet-derived growth factor (PDGF), C-X-C motif
chemokine 12 (CXCL12), galectin-1 and cytokines like IL-1, IL-6 to promote
pancreatic cancer progression and invasion [73, 74]. PSCs induce desmoplasia by
secretion of the main components of ECM, including collagens, fibronectin,
proteoglycans and glycosaminoglycans [75], leading to increased tumor interstitial
pressure, compressed blood vessels and hypoxia. They also control the ECM
turnover by secreting gelatinases, like MMP2, MMP9 to degrade the basement
membrane collagen and pave the way for cancer cell metastasis [76].
The deposition of ECM is associated with poor prognosis by promoting the
aggressiveness of PDAC and resistance to therapies. Tumor vasculature in PDAC is
profoundly affected by the excessive desmoplasia and antiangiogenic factors in the
TME. The compressed blood vessels and hypovasculature in PDAC largely limit
effective drug delivery. Hypoxia is a classic feature for most solid tumors including
pancreatic cancer. Hypoxia is the consequence of the high metabolic need for
oxygen as a result of the intensive cancer cell proliferation as well as insufficient
tumor vascular supply especially in PDAC. Hypoxia can activate numerous genes
through hypoxia-inducible factor (HIF) pathway to control cell metabolism, survival
and migration [71, 77].
Reducing the dense stroma represents a promising strategy for achieving better
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drug delivery efficacy. One strategy is to use inhibitors of the targets that build up the
tumor stroma. Sonic hedgehog (SHH) inhibitors [78, 79] are used for the depletion of
tumor stroma as SHH signaling is proved to enhance the desmoplastic reaction.
Another target is the secreted protein acidic and rich in cysteine (SPARC) [80], which
is overexpressed by fibroblasts in TME. Other strategies including enzymatic
degradation of the ECM scaffold, such as using hyaluronidase or collagenase to
degrade hyaluronic acid or collagens, which are the main ECM components.
1.2.3.2. PDAC immune cells
Immune cells make up about 50% of the tumor cells in PDAC [81]. The
immunosuppressive cell types, including T regulatory cells (Tregs), myeloid-derived
suppressor cells (MDSCs) and tumor associated macrophages (TAMs), greatly
outnumber the immunostimulatory CD8+ cytotoxic T cells, leading to the inhibition of
antitumor immunity. These major immune-suppressive cells are involved in the early
stages of the carcinoma (as early as PanIN stages) and high expressions are
associated with poor overall survival [82-84]. All of these immune cells have diverse
functions and participate in many steps during the PDAC progression.
CD8+ T cells play a pivotal role in killing cancer cells and a greater number of
CD8+ T cells correlate with longer survival [85]. However, their function is largely
impaired as a result of several immunosuppressing mechanisms in PDAC. The
activation of CD8+ T cells is inhibited by low expression of major histocompatibility
complex (MHC) class I molecules that present antigens for their activation [66, 86].
Moreover, the ability of CD8+ T cells to induce the apoptosis of the cancer cells is
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restricted by downregulated Fas expression [72]. There is also evidence that
intratumor CD8+ T cells express immune checkpoint molecules providing additional
immunosuppression [66, 87].
Tregs (CD4+ CD25+ FOXP3+) are a subset of T cells that are recruited by
pancreatic cancer cells and play an important role in immunosuppression by
downregulating the activation and proliferation of effector T cells [81, 88]. TGF-β
cytokine produced by the cancer cells favors CD4+ T cell differentiation into Tregs
through the induction of transcription factor FOXP3 [89] and Tregs can also secrete
cytokines like TGF-β and IL-10 to suppress the immune response [90, 91]. Tregs may
also induce effector T-cell apoptosis by cytotoxic enzymes such as granzyme B [92].
Cytotoxic T-lymphocyte associated protein 4 (CTLA-4) is highly expressed by Tregs
and can lead to the dysfunction of antigen-presenting dendritic cells (DCs) and inhibit
their maturation [93].
MDSCs are a heterogenous group of immune cells that are defined by their
myeloid origin, immature state and ability to suppress T cell responses. Granulocyte
macrophage colony-stimulating factor (GM-CSF) cytokine produced by cancer cells
due to the KRAS mutation [94] can induce the differentiation and recruitment of the
MDSCs into the TME [95, 96]. MDSCs can mitigate the immune surveillance function
of CD8+ T cells to induce immune evasion via production of TGF-β, reactive oxygen
species, nitric oxide synthase and depletion of L-arginine [97].
TAMs are a major population of immune cells heavily involved in cancer-related
inflammation in pancreatic TME. Macrophages can be divided into two phenotypes
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based on their activation mechanism. M1 macrophages undergo classical activation
by interferon γ (IFN-γ) and have pro-inflammatory and cytotoxic functions driving an
anti-tumorigenic response. M2 macrophages undergo alternative activation by IL-4
and tend to exert a pro-tumorigenic phenotype featured by their anti-inflammatory and
promoting tissue repair functions [98, 99]. The polarization of M1 and M2 phenotypes
depends on the various signals derived from immune cells and cancer cells. Factors
like CC chemokine ligand (CCL) 2 can attract TAMs into the TME. Their production of
vascular endothelial growth factor (VEGF) and MMPs is associated with induction of
angiogenesis and lympho-angiogenesis [100, 101], which are critical for metastasis.
They can also contribute to immunosuppression by secretion of cytokines and
chemokines, such as TGF-β, IL-10, IL-6, CCL2 and CCL17 [102]. For instance, TAMs
can stimulate PSC proliferation via TGF-β and contribute to desmoplasia [103]. IL-6
released by TAMs can activate the STAT3 signaling pathway to promote PDAC
development [104]. There are also studies show that TAMs impede CD8+ T cell
infiltration and dependent response by secretion of IL-10 to suppressing IL-12
expression from antigen-presenting DCs [105, 106].
Given the intricate roles immune cells are playing in the TME to escape immune
surveillance and promote pancreatic cancer progression, immunotherapy presents an
encouraging strategy for PDAC treatment. There are numerous clinical trials using
immunotherapy for PDAC therapy under evaluation. The expression of immune
checkpoint proteins programmed cell death-1 receptor (PD-1) and CTLA-4 on cancer
cell surface suppresses T cell activity and allows immune escape. Immune checkpoint
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inhibitors targeting these two proteins may be an effective way for stimulate the
immune response against cancer cells with combination of chemotherapy or
radiotherapy [107, 108]. Using an agonistic antibody against the costimulatory
molecule CD40 can activate antigen-presenting cells and also reprogram M2 TAMs
into tumoricidal M1 phenotype, facilitating tumor cell and stroma depletion [109].
Chimeric antigen receptor T-cell (CAR-T) therapy directly stimulates T cell mediated
immunity by reinjection of cultured T cells transfected with CAR gene into the host. It
is a personalized immunotherapy and several studies are under way in PDAC patients.
Other immunotherapies or immune-based targets for pancreatic cancer include
bacterial therapy, tumor-infiltrating lymphocyte (TIL) adoptive cell therapy, vaccine
therapy, C-X-C chemokine receptor type 4 (CXCR4), CD47, CCR4, or tyrosine-protein
kinase BTK.
1.2.4. PDAC metastasis
Metastasis of the cancer cells from the primary pancreatic site to distant sites is
the leading cause of mortality in PDAC. Liver, lung and peritoneum are the most
common sites of distant metastasis for pancreatic cancer patients. Metastasis forms
when cancer cells invade their surrounding tissue, enter the bloodstream, migrate
throughout the body, extravasate from the bloodstream into secondary sites and
acquire the ability of colonization at distant sites [110]. Although there are multiple
challenges cancer cells need to overcome for final colonization, the pro-tumorigenic
genetic alterations and immunosuppressive microenvironment pave the way for
successful metastasis.
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1.2.4.1. Epithelial-to-mesenchymal transition (EMT)
EMT in cancer is a process by which epithelial cells undergo morphological
changes and convert into elongated fibroblastic mesenchymal stem cells. It can be
recognized as the initiation step of the metastatic spread as cancer cells lose their cellcell adhesion capacity and break through the basement membrane for migration and
invasion during this process [111]. Epithelial cells can invade and enter the blood
stream to become circulating epithelial/cancer cells with mesenchymal-like phenotype
as early as PanIN [112] or IPMN [113] stages. The cells undergoing EMT show
downregulation of E-cadherin, which is an epithelial specific junction protein promoting
cell-cell contacts, and upregulation of mesenchymal molecular markers, such as Ncadherin, vimentin and fibronectin [114]. The process of EMT in PDAC is triggered by
convoluted molecular interplay between extracellular signals and growth factors
including TGF-β, MMPs, epidermal growth factor (EGF), fibroblast growth factor (FGF)
and PDGF [115]. Cellular elements, such as PSCs, TAMs and MDSCs can also
facilitate EMT and dissemination of pancreatic epithetical cells. For instance,
overexpression of galectin-1 which is secreted by PSCs correlates with enhanced EMT
marker expressions in PDAC mice [116]. MMPs produced by TAMs and PSCs can
decrease E-cadherin and their expression is considered as part of the EMT processes
[117].
1.2.4.2. Invasion, migration, angiogenesis, and lymphangiogenesis
Enhanced EMT leads to the mobility of the cancer cells needed to leave their
primary site. However, in order to metastasize, cancer cells need to reach and enter
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the blood vessels. The invasion and migration of pancreatic cancer cells to cancer
associated vasculature plays a vital role in this part. The TME facilitates the invasion
and migration by producing various factors. For example, CXCL12 (also known as cellderived factor 1, SDF-1) released by the cancer stroma cells can activate the
CXCR4/CXCL12 signaling and promote metastasis, which is reported by numerous
studies [118-120].
Metastasis is further facilitated by angiogenesis to establish neo-vasculature for
tumor nutrients and oxygen supply, as well as tumor-associated lymphangiogenesis
for lymph node metastasis. Angiogenesis and lymphangiogenesis for expansion of the
local and systemic tumor mass can be induced by multiple molecules released by
cancer and stroma cells. Among them, VEGF is one of the most important growth
factors that initiates angiogenesis and lymphangiogenesis. TAMs sense hypoxia in
avascular areas of the PDAC and react by producing VEGF-A and MMP9, which can
simultaneously induce both processes [121]. VEGF secretion is regulated by many
signaling pathways including IL-6/STAT3 [122] and NF-кB [123, 124]. The
overexpression of VEGF is typically observed in solid tumors, including PDAC, and the
upregulation is even elevated for maintenance of the vascular density and promoting
metastasis in late-stage tumors in an orthotopic PDAC mouse model [125]. Increased
VEGF expression also correlates with increased lymphatic vessel invasion and lymph
node metastasis in a statistical analysis of PDAC patients [126].
1.2.4.3. PDAC pre-metastatic niche
Factors derived from primary pancreatic TME can prepare the supportive
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microenvironment in the metastatic sites, which are called the pre-metastatic niche
[127]. The microenvironment changes at the premetastatic niche facilitate the
colonization of the circulating cancer cells once they reach the target sites. Similar
with the EMT, factors that can prepare the immunosuppressive environment in the
pre-metastatic niche include TGF-β, FGF, PDGF, TAMs, MDSCs and also exosomes
[72]. Exosomes represent as an important tool for intercellular communication
through the transfer of different biomolecules. A recent study demonstrated that
PDAC-derived exosomes with highly expressed migration inhibitory factor (MIF)
could be uptaken by liver Kupffer cells and lead to the secretion of TGF-β and
upregulation of fibronectin production by hepatic stellate cells. The fibrotic
microenvironment in the liver then promotes the recruitment of bone-marrow-derived
macrophages and neutrophils, establishing an immunosuppressive pre-metastatic
niche [128]. Another study showed that exosomes from primary tumors containing
microRNA (miRNA) contributed to target cell reprogramming in metastasis initiation in
a rat PDAC model [129]. Moreover, the microenvironment in the pre-metastatic niche
can also induce pancreatic cancer dormancy and contribute to disease recurrence.
1.2.5. CXCR4/CXCL12 signaling in PDAC
CXCR4 is among the most widely expressed chemokine receptors that belongs
to the large superfamily of G protein-coupled receptors (GPCR) in human cancers,
including pancreatic cancer. CXCR4 is highly expressed in PDAC and its
overexpression is correlated with advanced disease and poor clinical outcomes in
patients [130, 131]. Its ligand, CXCL12, is broadly expressed in variety of tissues.
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CXCL12 exclusively binds to CXCR4 and exerts the biological effects by activation of
multiple downstream signaling pathways that contribute to remodeling of the TME to
promote tumor proliferation, angiogenesis, metastasis and chemoresistance [132, 133].
1.2.5.1. Role of CXCR4/CXCL12 axis in PDAC
CXCR4/CXCL12 signaling plays an important role in pancreatic cancer metastasis.
High concentrations of CXCL12 are present in common sites of pancreatic metastasis
including liver, lung, and lymph nodes. This suggests the activation of CXCR4/CXCL12
axis can facilitate the homing of pancreatic cancer cells to specific organs by
chemotaxis [119, 134]. There is also evidence that CXCR4/CXCL12 signaling can
induce pancreatic cancer cell invasion and EMT through non-canonical activation of
Hedgehog pathway in vitro [135]. Moreover, this axis is also involved in angiogenesis
and lymphangiogenesis [136] by facilitating secretion of VEGF and MMPs [133, 137].
CXCR4/CXCL12 axis can facilitate cancer cell proliferation and contribute to
chemoresistance as well. Studies show that CXCR4/CXCL12 signaling leads to
upregulation of SHH in pancreatic cancer cells through the activation of AKT and ERK
signaling pathways, which can promote desmoplastic reaction and cancer cell
proliferation [138, 139]. The resultant dense stroma cells induce additional CXCL12
and this positive feedback loop not only supports cancer progression, but also presents
the physical barrier for drug delivery. The induced activation of ERK and AKT pathways
promote the nuclear accumulation of β-catenin and NF-кB, resulting in the secretion of
pro-survival factors, such as Bcl-2, Bcl-xL, and survivin [140, 141]. In one study,
significant protection effect of pancreatic cancer cells from gemcitabine toxicity was
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observed when co-treated with CXCL12, indicating the role of CXCR4/CXCL12
signaling in PDAC chemoresistance [140]. There is also evidence that the treatment
of pancreatic cancer cells with gemcitabine can even induce CXCR4 expression [142,
143] promoting more aggressive PDAC phenotype.
1.2.5.2. CXCR4-targeted therapy for PDAC treatment
As

CXCR4/CXCL12

signaling

promotes

metastasis,

proliferation

and

chemoresistance properties, it is considered as a potential therapeutic target for
treatment PDAC. Blocking CXCR4/CXCL12 interaction using CXCR4 antagonists is
an effective strategy, especially when combined with other therapies, such as
chemotherapy, radiation therapy, or immunotherapy.
AMD3100 is an FDA approved small molecule inhibitor of CXCR4. Treatment with
AMD3100 is proven to be effective in abrogation of the invasion and proliferation
effects of CXCR4/CXCL12 signaling [120, 135] and alleviation of gemcitabine
resistance in pancreatic cancer cells [140]. The combination treatment of AMD3100
with α-PD-L1 works synergistically in diminishing cancer cells and inducing T cell
infiltration into the tumors [144]. Our group has developed the polymeric CXCR4
inhibitors with repeating AMD3100 units, which are capable of simultaneously inhibiting
CXCR4 and delivering of nucleic acids. These multi-functional therapies also showed
the effectiveness in inhibition of both primary tumor growth and metastasis in various
cancer types, including PDAC [143, 145]. The small molecule compounds chloroquine
and hydroxychloroquine, the classic anti-malarial drugs, are also found to be the
promising agents that can effectively inhibit CXCR4 in PDAC [146].
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Targeting CXCR4 with RNA interference (RNAi) techniques have also been
reported to inhibit pancreatic cancer cell progression in vitro. Singh et al. used CXCR4targeted small interfering RNA (siRNA) and proved it was able to effectively silence the
CXCR4 gene in MiaPaCa and Colo357 PDAC cells and abrogate the CXCL12-induced
SHH expression [138]. Similarly, Weekes et al. demonstrated that the use of short
hairpin RNA (shRNA) targeting CXCR4 can specifically inhibit CXCL12-induced AKT
phosphorylation to regulate mTOR pathway activation [147].
Other CXCR4-targeted methods in PDAC include CXCR4-targeted tumor imaging
using radiolabeled peptide or anti-CXCR4 antibody conjugated to nanoparticles.
Hanaoka et al. developed a

In-labeled peptidic CXCR4 inhibitor Ac-TZ14011 [148].
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It was shown to inhibit the binding of CXCL12 to CXCR4 in CXCR4-transfected CHO
cells and to accumulate more in the CXCR4-expressing tumors than in blood or muscle
in an AsPC-1 derived PDAC mouse model, which made it a potential
radiopharmaceutical for CXCR4-expressing tumor imaging. Another group established
a CXCR4-targeted nanoparticle contrast agent called CXCR4-USPIO for pancreatic
cancer cell MR imaging [149]. It could be used to semi-quantitatively estimate the
CXCR4 expression level based on the T2 enhancement ratio and ΔR2 values, which
might be helpful for the diagnosis and prognosis of PDAC patients.
1.3. RNA interference therapy
RNAi is a potent gene silencing process in which small RNA molecules like miRNA
or siRNA regulate target gene expression or translation by sequence-specific
degradation of the targeted mRNA, leading to the inhibition of downstream protein
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translation [150]. siRNAs are synthetic RNA duplexes with 20-25 base pairs in length.
After entering the cytoplasm, siRNA binds to RNA-induced silencing complex (RISC).
With the passenger strand of siRNA cleaved, the guide strand guides pairing of the
activated RISC with the targeted mRNA and induce the mRNA cleavage by Argonaute,
a catalytic component of RISC [151, 152]. The mechanism of miRNA gene silencing is
similar with that of siRNA, but the miRNA is able to regulate multiple genes
simultaneously due to a partial complementary base pairing [153, 154], resulting in the
degradation, cleavage or translation repression of mRNAs.
The advantages of RNAi, such as applicability to nearly any therapeutic target,
high selectivity, potency, low toxicity and easy synthesis [155, 156] makes it an area of
intense interest. RNAi represents a promising therapeutic strategy for various diseases.
Significant progress has been made in RNAi therapy over the years with multiple RNAi
therapeutics going into clinical trials [157-159]. Encouragingly, FDA has approved two
RNAi drugs in 2018 and 2019. The first approved RNAi drug is patisiran from Alnylam
for the treatment of polyneuropathy in patients with hereditary transthyretin-mediated
amyloidosis using transthyretin gene targeted siRNA [160]. The second drug is
givosiran from the same company for the treatment of the acute hepatic porphyria by
targeting aminolaevulinic acid synthase 1 with siRNA. With that, RNAi is no longer a
concept, but a feasible approach that can achieve positive therapeutic effects in human
diseases.
1.3.1. Potential of RNAi therapy for the treatment of PDAC
As PDAC presents very complicated genetic alteration profiles with numerous
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signaling pathways and diverse somatic mutations involved in the tumorigenesis and
progression [161, 162], the complexity of this disease results in the failure of clinically
used conventional drugs. RNAi can provide benefits that conventional small molecule
drugs may not achieve, especially in that RNAi provides opportunities for drugging of
many currently ‘undruggable’ targets, such as the highly mutated KRAS gene in PDAC
[163, 164]. There have been plenty of pre-clinical studies showing effective inhibition
of PDAC tumor growth in vitro and in vivo by siRNA [165-167]. Nevertheless, very few
of them entered clinical trials. Challenges present for the translational medicine to
benefit PDAC patients, yet RNAi remains to be a hopeful strategy. We expect better
therapeutic results if we can achieve multiple targeting by delivery of several small
RNAs altogether with or without chemotherapy or radiotherapy combinations.
1.3.2. Delivery strategies for small RNAs
Regardless of the potential therapeutic advantages of RNAi, the delivery of small
RNAs is another story. There are inherent delivery hurdles for small RNAs, including
poor cellular permeability, and off-target effects [168]. In order to solve these problems
and achieve better delivery efficacy, chemical modification of the small RNAs or
delivery vectors were extensively explored.
Chemical modifications of the siRNAs at 2’-position of the pentose sugar and 3’or 5’-ends with low molecular chemical structures, polymer, peptides have been
extensively studied [169, 170]. However, the modification may impair the biological
efficacy of the siRNAs, and the complex preparation and high cost further limit it use.
RNA delivery by vectors may be a better way to tackle with the inherent pitfalls.
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An ideal RNA delivery system should overcome multiple biological barriers and have
properties including RNA degradation protection, tumor-specific targeting, increased
circulation, improved tumor cell uptake and penetration, low immunogenicity, and easy
preparation [168, 171].
Viral and non-viral vectors are two main categories of delivery systems for siRNA
and miRNA. The most commonly used viral vectors are retrovirus, adenovirus,
adenovirus-associated viruses, and herpes simplex virus vectors. Viruses offer high
transfection efficacy and long-term gene expression, but their application is limited by
associated toxicity, immunogenicity and the inner complexities of this method [172].
The widely used non-viral vectors include cationic lipids and cationic polymers.
Through electrostatic interaction, the cationic lipids or polymers can bind the anionic
small RNAs and form nano-sized particles. Main classes of lipid-based nanocarriers
include liposomes, solid lipid nanoparticles, and lipid nanoemulsions [173]. The use of
biocompatible and biodegradable lipids can enhance the cellular uptake [174] of the
nanoparticles with low risk of immunogenetic reactions. However, they are also
associated with high production costs and some other issues, such as low stability for
lipid nanoemulsions and exposure of small RNAs at carrier surfaces for liposomes and
solid lipid nanoparticles [173]. Cationic polymers are chemically synthesized high
molecular weight compounds that can form polyelectrolyte complexes (polyplexes)
with RNAs. A lot of efforts have been put into the design of the polymers to achieve all
kinds of purposes. For instance, polyethylene glycol can reduce toxicity and improve
in vivo circulation [175]. The modification with tumor targeting and penetrating moieties
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(e.g. folic acid, specific antibodies, and peptides) can facilitate specific tumor targeting
and penetration [176]. The introduction of stimuli-responsive linkers (pH, ROS, light,
ATP) can promote dissociation of the nanoparticles and release siRNA/miRNA into the
cytoplasm for the inhibition purpose [177]. Polymers can also be designed to
chemically conjugate therapeutic drugs to achieve multivalency effect and being dualfunctional [178, 179]. In general, polymer-based delivery vectors can improve stability,
facilitate endosomal escape, provide functionalized corona and being easy
manufactured, yet it is associated with lower transfection efficacy compared to lipidbased vectors. Ultimately, we are expecting simpler formulation of delivery vehicles
with good transfection efficacy, so that they can be more easily translated to future
clinical use with better quality controls and less unexpected adverse effects.
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Chapter 2. Effect of administration route on the delivery efficacy in orthotopic
PDAC model
Please note that parts of Chapters 2 and 3 were published in a journal ACS
Nano in a paper titled “Stromal modulation and treatment of metastatic pancreatic
cancer with local intraperitoneal triple miRNA/siRNA nanotherapy” [180]. As the cofirst authors, Ying Xie and I contributed equally as we did all the animal study
together and equal amount of work for in vitro studies. All the other authors helped
with parts of the experiments, data analysis, or provided general suggestions. Ying
Xie and Dr. Oupicky wrote the manuscript. Dr. Oupicky conceived and supervised the
study. All the authors agreed with including their work in this dissertation.
2.1. Introduction
Nanoscale vectors have been widely used to deliver drugs and nucleic acids to
tumors of various origins. These nanomedicines are typically injected IV into the body
and then rely on extravasation through leaky tumor blood vessels to accumulate in the
tumors based on the so-called enhanced permeability and retention (EPR) effect [181].
Unfortunately, as PDAC features dense stroma and compressed blood vessels, IV
administration represents a suboptimal delivery method for nanomedicines without
clear benefits from limited EPR effect [182]. Some studies have reported strategies to
overcome the stromal barrier in PDAC by engineering the carrier systems [183, 184].
However, such carrier engineering often leads to complexity that diminishes their
translational potential. Localized delivery represents a potential strategy to overcome
these limitations for PDAC drug delivery, yet there is lack of versatile local delivery
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systems [185]. IP delivery has been recently proposed as an alternative administration
strategy to deliver nanomedicines to peritoneal tumors, including PDAC [186]. After IP
administration, the nanomedicines directly enter the tumor from peritoneal fluid, which
can gain more opportunities for direct contact of tumors with high therapeutic
concentrations [187]. IP delivery maximizes local efficacy while potentially limiting
systemic side effects. It is believed that IP injected particles localize to peritoneal
tumors instead of normal organs due to differences in the surface mesothelium.
Abdominal organs are covered by peritoneum with intact mesothelium and
submesothelial fibrous connective tissue, which act as a barrier against the adhesion
and entry of nanoparticles through the surface of the organs [188]. In contrast,
peritoneal tumors usually are devoid of these surface coverings due to the disruption
of peritoneal mesothelial cells during tumor progression as a result of the interaction
of cancer cells with the peritoneum [189-191]. Overall, local delivery by IP
administration provides an effective alternative to IV administration and holds potential
for tumor-specific localization of nanoparticles in PDAC.
In this chapter, we describe the comparison of IV versus IP administration of the
nanoparticles we previously developed in our lab in a murine orthotopic PDAC model.
The approach is based on the dual-functional nanoparticles composed of cholesterol
modified polymeric AMD3100 (PAMD-CHOL) and siRNA. It is proved to simultaneously
antagonize CXCR4 and efficiently down regulate specific genes both in vitro and in
vivo [143, 145]. With the result of a better drug administration route, we expect to get
improved therapeutic efficacies for PDAC treatment.
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2.2. Materials and methods
2.2.1. Materials
Dulbecco’s phosphate buffered saline (PBS), Dulbecco’s modified Eagle medium
(DMEM), fetal bovine serum (FBS), trypsin and penicillin/streptomycin (Pen-Strep)
were purchased from Thermo Scientific (Waltham, MA). Carboxyfluorescein-labeled
siRNA (FAM-siRNA) (sense sequence, 5′-FAM- AUGAACGUGAAUUGCUCAA -3′)
were from Dharmacon (Lafayette, CO). AMD3100 was obtained from Biochempartner
(Shanghai). N,N’-Hexamethylenebisacrylamide (HMBA) was from Pfaltz&Bauer
(Waterbury, CT). Cholesteryl chloroformate was obtained from Sigma-Aldrich (St.
Louis, MO). N, N-diisopropylethylamine (DIPEA) was from Acros Organics (Fair Lawn,
NJ). Anti-α-SMA (Catalog #: ab5694) and anti-CD31 (Catalog #: ab28364) antibodies
were bought from Abcam (Cambridge, MA). Other reagents were provided by Fisher
Scientific and used as received unless stated otherwise.
2.2.2. Methods
2.2.2.1. Synthesis and characterization of the polymer
PAMD-CHOL was synthesized and characterized as previously described [192,
193]. Michael polyaddition of AMD3100 and HMBA resulted in the polymeric AMD3100.
The equal molar ratio of HMBA (1.0 mmol, 224.3 mg) and AMD3100 (1.0 mmol, 502.78
mg) were dissolved in 9 mL methanol/water (7/3 v/v) mixture. The glass vial with the
reactants was purged with nitrogen and the reaction was carried out at 37 °C for 3
days in the dark. Then, an additional 0.1 mmol of AMD3100 was added to consume
the residual acrylamide groups. The reaction mixture was dialyzed against methanol
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(3500 MWCO) for one day. Then, methanol was evaporated and polymeric AMD3100
was further dried in vacuum. The final product of PAMD polymer was 660.2 mg with
an overall yield of 90.8%. The structure of polymeric AMD3100 was confirmed by 1HNMR in the solvent of methonal-d4 using Varian INOVA (500 MHz). The molecular
weight was determined by gel permeation chromatography (GPC) using Agilent 1260
Infinity LC system with a miniDAWN TREOS multi-angle light scattering detector and
an Optilab T-rEX refractive index detector (Wyatt Technology, Santa Barbara, CA).
TSKgel G3000PWXL-CP column (Tosoh Bioscience LLC, PA) was used at a flow rate
of 0.5 mL·min−1 (sodium acetate buffer, pH 5). Astra 6.1 software was used to analyze
results.
Cholesterol was conjugated to polymeric AMD3100 by reaction with cholesteryl
chloroformate. Polymeric AMD3100 (650 mg) and DIPEA (346.6 mg, 2.68 mmol) were
dissolved in anhydrous methylene chloride. Cholesteryl chloroformate (140.5 mg, 0.31
mmol) was dissolved in anhydrous methylene chloride and added dropwise into the
polymeric AMD3100 solution in ice-bath. The reaction was carried out overnight, and
the product was purified by dialysis against methanol (3500 MWCO) for one day,
followed by dialysis against HCl solution (pH = 4) for one day and deionized water for
another day. The final PAMD-CHOL product was obtained as a hydrochloride salt
through lyophilization. The yield of PAMD-CHOL is around 78%. The structure of
PAMD-CHOL and the amount of conjugated cholesterol were characterized by 1HNMR on Varian INOVA (500 MHz). Succinimidyl ester of Alexa Fluor® 647 carboxylic
acid (Life Technologies, OR) was conjugated to PAMD-CHOL to obtain AlexaFluor 647
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labeled PAMD-CHOL (AF647-PAMD-CHOL) following the manufacturer’s protocol.
2.2.2.2. Cell culture
Primary tumor cell line KPC8060 derived from PDAC mouse model KPC (KrasLSL
‑ G12D/+

; Trp53LSL ‑ R172H/+; Pdx-1-Cre) was provided by Dr. Hollingsworth at UNMC.

Human epithelial osteosarcoma U2OS cells (Fisher Scientific) with functional EGFPCXCR4 fusion protein expressing were cultured in DMEM with 10% FBS, 2 mM Lglutamine, 0.5 mg/mL G418 Sulfate and Pen-Strep (100 U/mL, 100 μg/mL). All the
cells were cultured in high-glucose DMEM with 10% FBS, penicillin (100 U/mL),
streptomycin (100 μg/mL) at 37 °C with 5% CO2 in a humidified chamber.
2.2.2.3. CXCR4 antagonism assay
CXCR4 redistribution assay was employed to determine the CXCR4 antagonism
efficacy of compounds. U2OS cells with the EGFP-CXCR4 fusion protein (Fisher
Scientific) were cultured in DMEM with 2 mM L-glutamine, 10% FBS, 1% Pen-Strep
and 0.5 mg/mL G418. Cells were seeded in black 96-well microplates 24 h before
treatment. Cells were washed with assay buffer before treatment and then treated with
tested compounds for 30 min. CXCL12 was added for another 1 h incubation. Cells
were fixed and stained with Hoechst 33258. Quantification of the internalization of the
CXCR4 receptors was performed with Cellomics ArrayScan V High Content Analysis
Reader (Thermo Scientific) and SpotDetectorV3 BioApplication software. Doseresponse curves were obtained based on % CXCR4 internalization calculated relative
to the AMD3100 group (100%) and CXCL12 only group (0%). EC50 value
(concentration inducing 50% CXCR4 antagonism) of tested compounds was
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calculated with Prism GraphPad software. Images were taken by confocal microscopy
(LSM800 Laser Scanning Microscope, Zeiss, Jena, Germany).
2.2.2.4. Preparation and characterization of nanoparticles
PAMD-CHOL/siRNA nanoparticles were prepared by mixing equal volume of
PAMD-CHOL and siRNA solutions at (polymer/siRNA) weight ratio of 2 in HBG buffer
(20 mM HEPES, pH 7.4) and vortexing for 10 s. Nanoparticles were incubated at room
temperature for 20 min before use.
2.2.2.5. Orthotopic pancreatic cancer model
All animal studies were following the protocol approved by the University of
Nebraska Medical Center Institutional Animal Care and Use Committee. Orthotropic
KPC pancreatic cancer mouse model was established by pancreatic injection of
KPC8060 cells as previously described. Male C57BL/6 mice (6 weeks old) purchased
from Charles River Laboratories were anesthetized by IP injection of ketamine/xylazine
solution. The surgical site was sterilized by iodine and alcohol pad and an incision was
made in the peritoneum at the left-central abdomen region. Pancreas was exposed
through the incision and 2.5 × 104 of KPC8060 cells suspended in 1:1 mixture of
PBS/Matrigel were injected into the tail of the pancreas. The abdomen was closed with
5-0 chromic catgut and soft staple. The staples were removed 7 days after surgery.
2.2.2.6. Blood circulation time
Orthotopic pancreatic tumor-bearing mice (3 weeks after tumor implantation,
tumor diameter ~10 mm) were IV or IP administrated with 200 µL of AF647-PAMDCHOL/FAM-siRNA nanoparticles (5 mg/kg AF647-PAMD-CHOL, 2.5 mg/kg FAM-

38

siRNA). At 2 min, 0.25 h, 1 h, 4 h, and 24 h post injection, about 100 µL blood from the
retro-orbital venous plexus of each mouse was collected in heparin-treated tubes and
imaged with Xenogen IVIS 200 (Ex = 640 nm, Em = 680 nm) which was followed by
fluorescence analysis by the instrument software.
2.2.2.7. Biodistribution
Orthotopic pancreatic tumor-bearing mice (tumor diameter ~10 mm) were IV or IP
injected with 200 µL of AF647-PAMD-CHOL/FAM-siRNA nanoparticles (5 mg/kg
AF647-PAMD-CHOL, 2.5 mg/kg FAM-siRNA). At 4 and 24 h post injection, mice were
sacrificed and imaged using Xenogen IVIS 200 (Ex = 640 nm, Em = 680 nm). Tumors
and major organs were also harvested for ex vivo fluorescence imaging. For CXCR4
receptor competition assay, anti-CXCR4 antibody (UMB2, Abcam) was IP injected into
mice (100 µg/mouse) 30 min before nanoparticles administration. The instrument
software was used to analyze the fluorescence signal from each tumor or organ.
Tumors were embedded in an OCT compound, cut into 10 μm frozen sections, stained
with CD31 antibody (Cy3) and observed using a confocal microscope. Tumor samples
were also stained with α-SMA antibody (Cy3) to label PSCs and visualized under a
confocal microscope. Moreover, we performed H&E staining to study the mesothelium
of tissues and tumors of the orthotopic PDAC model. We also analyzed mesothelium
in KPC mice with spontaneously developed tumors and in samples from human PDAC
patients. Section slides from the wild-type KPC mice were provided by Dr.
Hollingsworth at UNMC. The WT KPC mice carry the PDX-1-Cre transgene, the LSLKRASG12D knock-in mutation and the LSL-Trp53R172H knock-in mutation. Sections were
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collected from WT KPC mice at age of 19-21 weeks at which stage the animals develop
primary pancreatic tumor and peritoneal metastasis. The section slides of healthy
human pancreas and liver tissues, and PDAC patient primary pancreatic tumor and
liver metastases were obtained from the UNMC Rapid Autopsy Program with informed
consent from all patients and approval from Institutional Review Board.
2.2.2.8. Histochemical analysis
Tumor or organ sections were stained with hematoxylin and eosin (H&E). The
H&E stained slides were observed under an EVOS xl microscope (Thermo, USA) and
histopathological changes were analyzed by a pathologist. For immunofluorescence
staining, tumor slides were treated with endogenous peroxidase inhibitor, incubated
with primary antibody at 37 °C for 32 mins, incubated with horseradish peroxidase
(HRP)-conjugated secondary antibody at 37 °C for 32 mins, and incubated with
Discovery FITC Kit (Roche). Sections were also counterstained with 4′,6-diamidino-2′phenylindole dihydrochloride (DAPI) for nucleus visualization. Immunofluorescence
slides were mounted with antifade reagent and observed using a confocal microscope
(LSM 800).
2.2.2.9. Statistical analysis
Results are presented as mean ± SD. Students t -test was used to analyze the
statistical significance between the two groups. P < 0.05 was considered as a minimal
level of significance. All statistical analysis was performed with GraphPad Prism v5.
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2.3. Results and discussion
2.3.1. Synthesis and characterization of PAMD-CHOL
PAMD-CHOL was synthesized by Michael addition copolymerization of AMD3100
with hexamethylene bisacrylamide and covalently modified with an optimized amount
of cholesterol to improve the in vivo stability and effectiveness (Figure 2.1A). The
composition and molecular weight of PAMD-CHOL were characterized by 1H-NMR and
GPC. The PAMD-CHOL used in the present study had a weight-average molecular
weight (Mw) of 14.4 kg/mol with Đ of 1.2 and the cholesterol weight content 16.7%
(Figure 2.1B, C). CXCR4 antagonism of PAMD-CHOL was validated using a CXCR4
receptor redistribution assay (Figure 2.1D, E). Upon the activation of CXCR4/CXCL12
signaling, internalization of the membrane-localized CXCR4-EGFP fusion protein will
be induced. AMD3100 at 300 nM was set as 100% CXCR4 inhibition. PAMD-CHOL
displayed a dose-dependent CXCR4 antagonism with complete inhibition observed at
2 µg/mL (~140 nM). Negative control polyethyleneimine (PEI) showed no CXCR4
inhibition, which excluded the possibility that CXCR4 antagonism of PAMD-CHOL is
caused by nonspecific electrostatic binding of polycations to the negatively charged
active site of the CXCR4 receptor. The nanoparticles used in this study were prepared
by mixing the PAMD-CHOL polymer and FAM-siRNA at weight ratio (w/w) of 2, which
was determined as the best working formulation in our previous studies [194].
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Figure 2.1. Synthesis and characterization of PAMD-CHOL. (A) Reaction scheme of
PAMD-CHOL. (B) 1H-NMR spectrum of PAMD-CHOL in Methanol-d4 for determination
of the cholesterol content. (C) Molecular weight analysis. (D) The CXCR4 receptor
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redistribution assay was conducted in U2OS cells expressing GFP-tagged CXCR4
(green). Nucleus was stained with DAPI (blue). AMD3100 (300 nM), PAMD-CHOL (2
µg/mL), PEI (2 µg/mL). Scale bar = 100 µm. (E) EC50 values determined from receptor
redistribution assay in U2OS cells (n = 3).

2.3.2. Comparison of IV and IP nanoparticle biodistribution in orthotopic PDAC
mice
KPC8060 cells with mutant KRASG12D and p53 were orthotopically implanted in
the tail of the pancreas of immunocompetent C57BL/6 mice to establish orthotopic
PDAC model. This model mimics human disease with similar oncogene expression,
tumor growth characteristics, metastasis profile, and desmoplastic stroma reaction
[165, 195]. Small primary pancreatic tumors with limited metastases (except for local
splenic invasion) were found as early as 2-3 weeks after cell implantation. Large
orthotopic tumors and widespread metastasis were observed after 4-5 weeks (Figure
2.2).
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Figure 2.2. Progression of orthotopic KPC8060 cell derived pancreatic cancer in mice.
Mice were sacrificed at indicated times after tumor implantation. Tumor and tissues
were harvested for observation. Arrows indicate local invasion or metastasis.

We first compared IV and IP administration in terms of the plasma circulation time.
Equal doses of AF647-PAMD-CHOL (100 μg)/FAM-siRNA (50 μg) nanoparticles were
injected either IV (200 μl) or IP (500 μl) in the PDAC tumor-bearing mice. The AF647PAMD-CHOL fluorescence intensity in blood was normalized by setting intensity at 2
min after IV injection as 100% (Figure 2.3A, B). After IV injection, the blood
fluorescence signal decreased rapidly to ~18% at 1 h post-injection and the signal
almost disappeared by 24 h due to fast clearance of the nanoparticles from the blood.
Prolonged peritoneal retention and limited systemic absorption are important for
effective IP treatment [196]. When evaluating the peritoneal retention of IP-injected
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nanoparticles, we observed widespread local retention of the nanoparticles at 4 h postinjection. The detected amount was significantly reduced after 24 h (Figure 2.3C).
Nanoparticles are expected to be absorbed into the blood from the peritoneal cavity
[187] and susceptible to clearance from the peritoneal cavity mainly as a result of
lymphatic drainage [197]. As expected, the content of the nanoparticles in blood was
increasing after IP injection and reached ~17% at 1 h, which was followed by a
complete clearance at 24 h. The fluorescence intensity in blood after IP injection is a
function of absorption from the peritoneal cavity and reticuloendothelial system (RES)
clearance from the blood. We estimated the area under the curve (AUC) for both IV
and IP administration and found that AUC0-∞ of the IP injection was ~67% of the AUC
observed in the IV injection. The results suggested that a significant portion of the IPinjected nanoparticles was retained in the peritoneum and not absorbed into the blood
circulation.
To study the biodistribution of the nanoparticles, AF647-PAMD-CHOL/FAM-siRNA
was injected IV or IP in mice with orthotopic pancreatic tumors. Following animal
sacrifice at 4 and 24 h post injection, we measured the fluorescence of the AF647PAMD-CHOL in the isolated tissues. In the mice given IV injection, the nanoparticles
mainly accumulated in the liver and showed very poor tumor distribution at both 4 and
24 h after injection. The nanoparticles were also found in the spleen and the lung
(Figure 2.3D, E). In the animals given IP injection, significant accumulation of the
nanoparticles in the orthotopic tumors was observed. Mean fluorescence intensity (MFI)
of AF647-PAMD-CHOL in the tumors was nearly 5-fold higher than in the case of the
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IV treatment at 4 h post-injection. The relative tumor accumulation in the IP group
further increased with time, reaching nearly a 15-fold higher level relative to the IV
group at 24 h (Figure 2.3D, E). In comparison with the IV group, the IP injected animals
also showed substantially decreased hepatic and splenic accumulation of the
nanoparticles, most likely due to lower clearance by the RES. Since an estimated 67%
of the IP injected nanoparticles were absorbed into the systemic circulation, it is
interesting that the hepatic distribution in the IP group was only 20% of the IV group.
Besides the limitations of fluorescence in quantifying biodistribution of nanoparticles
[198], IP administration may result in engaging different metabolic routes, different
protein adsorption profile, and faster biliary excretion in comparison with IV injection
[199], which could lead to lower liver accumulation of IP injected nanoparticles.
Moreover, we observed the distribution of the nanoparticles in the peritoneal metastatic
lesions. A significant increase in the distribution of the nanoparticles was found in local
splenic invasion compared with normal spleen tissue (Figure 2.3F). These results
confirmed the superior capability of the EPR-independent delivery by IP-injected
nanoparticles to deliver both PAMD-CHOL and siRNA to pancreatic tumors and
peritoneal metastases.
To evaluate if CXCR4-dependent tumor uptake is involved in the observed
findings, we have pre-injected the animals with anti-CXCR4 antibody to block the
CXCR4 receptor in the tumor before nanoparticles injection. Biodistribution of the IP
injected nanoparticles in the mice with CXCR4 blockade was compared with that in
mice without the blockade. We found that the blockade of CXCR4 receptor did not
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reduce the tumor localization of the IP injected nanoparticles (Figure 2.3G). This result
demonstrates that tumor accumulation of the IP injected nanoparticles is likely
independent of the CXCR4 receptor binding.

Figure 2.3. Pharmacokinetics and biodistribution of the nanoparticles in orthotopic
pancreatic cancer mice by IV and IP administration. All the mice were injected with the
same dose of the nanoparticles (w/w = 2 and 5 mg/kg AF647-PAMD-CHOL, 2.5 mg/kg
FAM-siRNA). All the fluorescent images were taken under a fluorescence imaging IVIS
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system at Ex = 640 nm, Em = 680 nm. (A) Blood fluorescence (AF647) over time after
IV or IP injection of AF647-PAMD-CHOL/FAM-siRNA nanoparticles. Results are
expressed as relative fluorescence intensity ± SD (n = 3). (B) Curves of relative
fluorescence intensity in blood over time. (C) Peritoneal retention of nanoparticles after
IP administration of the nanoparticles at 4 and 24 h after injection. (D) Ex vivo
fluorescence images of the primary tumors and organs taken from the orthotopic PDAC
mice at 4 h after injection of nanoparticles. Fluorescence intensities were
semiquantified by IVIS software at 4 h after injection. (E) Ex vivo fluorescence images
of the primary tumors and organs taken from the orthotopic PDAC mice at 24 h after
injection of nanoparticles. Fluorescence intensities were semiquantified by IVIS
software at 24 h after injection. (E) Ex vivo distribution of nanoparticles in the spleen
with tumor invasion at 24 h after IP injection. (F) Comparison of the distribution of
nanoparticles in primary tumors at 24 h after IP injection in mice with/without antiCXCR4 antibody pretreatment. Results are expressed as mean fluorescence intensity
± SD (n = 3). **P < 0.01, ***P < 0.001.

2.3.3. Comparison of nanoparticle intratumor distribution by IV and IP
administration
To obtain detailed information about the distribution of the nanoparticles within the
tumors, frozen tumor sections obtained 24 h post IV or IP injection were analyzed using
confocal microscopy. While minimal fluorescent signals from AF647-PAMD-CHOL (red)
and FAM-siRNA (green) were observed in primary tumors treated by IV injection of the
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nanoparticles, both fluorescence signals were intensively present in the primary
tumors of IP-injected mice, suggesting delivery of assembled nanoparticles (Figure
2.4A). Importantly, the nanoparticles were delivered to both peripheral and central
regions of the pancreatic tumors as indicated by the widespread fluorescence
distribution by IP administration. We observed pronounced nanoparticle localization on
the tumor surfaces but limited perivascular distribution, which suggested that the
nanoparticles penetrated the tumors directly from the peritoneal cavity without any
significant contribution of the blood-circulating particles (Figure 2.4A, B). Interestingly,
in the IP-injected mice, polymer fluorescence was observed in the nucleus of the tumor
cells. However, little siRNA fluorescence was shown in the nucleus (Figure 2.4B). This
result suggested that polymers rather than the whole nanoparticles effectively entered
nucleus. After being injected into the body for 24 h, a part of nanoparticles possibly
disassembled to free polycation and siRNA. The siRNA exerts its role in the
cytoplasma while the free polycation might be able to cross nuclear pore because of
the smaller size (~5 nm ) [200]. In addition to the cancer cells within the tumors, the
nanoparticles were also found in activated PSCs which expressed α-SMA (Figure
2.4C), which may help modulate the TME.
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Figure 2.4. Intratumor distribution of nanoparticles by IV and IP administration. (A)
Confocal microscopy images of frozen tumor sections at 24 h after injection with tumor
margins and part of the central regions. PAMD-CHOL is shown in red (AF647), siRNA
in green (FAM), blood vessels in white (Cy3), and the nuclei in blue (DAPI). (B)
Enlarged version of (A) showing nanoparticle distributions in tumor central regions. (C)
Confocal images of frozen tumor sections at 24 h after injection. PAMD-CHOL is shown
in red (AF647), siRNA in green (FAM), α-SMA expressing PSCs in magenta (Cy3) and
the nucleus in blue (DAPI).
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2.3.4. Possible mechanism for improved drug delivery by IP administration
To explore the reasons for the high tumor accumulation of the PAMD-CHOL/siRNA
nanoparticles, we first analyzed tumor surface peritoneum as a barrier for IP delivered
nanoparticles [187, 191]. We examined the H&E stained tissue slides of normal organs,
primary pancreatic tumors, and metastatic lesions in various other organs. We found
that, as compared to the normal organ (like pancreas and kidney), primary pancreatic
tumors and other organs containing metastatic foci lacked the visceral peritoneum
which is normally composed of flat mesothelial cells (mesothelium/mesothelial lining)
(Figure 2.5A). In some instances, we also observed the presence of a fibrous capsule
at tumor margins. In accordance, the characteristic lack of mesothelium on the tumor
surfaces was also observed in spontaneously developed tumors in genetically
engineered KPC mice (Figure 2.5B) and in human PDAC patient samples (Figure
2.5C). Thus, we hypothesize that the lack of compact mesothelial lining is likely
contributing to the tumor localization of the nanoparticles after IP injection of the
nanoparticles and this finding could be holding applicability and clinical translatability
to human medicine.
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Figure 2.5. H&E staining of the tumors and healthy tissues from different pancreatic
cancer models. (A) H&E staining of tumor and healthy tissues in orthotopic PDAC mice
(I) normal pancreas with mesothelial lining (black arrow), scale bar = 100 μm, (II)
normal kidney (without metastasis) with mesothelial lining (black arrow), scale bar =
100 μm, (III) normal pancreas with mesothelium (black arrow) and tumor with capsule
(red arrow) but no mesothelium in single section, scale bar = 100 μm, (IV) primary
pancreatic tumor with capsule (red arrow) but no mesothelium, scale bar = 100 μm, (V)
liver metastasis without mesothelium, scale bar = 100 μm, (VI) spleen metastasis
without mesothelium, scale bar = 500 μm. (B) H&E staining of tumor and healthy
tissues in genetically engineered KPC mice (I) normal pancreas with mesothelial lining
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(black arrow), scale bar = 100 μm, (II) primary pancreatic tumor without mesothelium,
scale bar = 100 μm, (III) liver metastasis with broken mesothelium (black arrow), scale
bar = 100 μm. (C) H&E staining of tumor and healthy tissues in Human PDAC patient
(I) normal pancreas with mesothelial lining (black arrow), scale bar = 100 μm, (II)
primary pancreatic tumor without mesothelium, scale bar = 100 μm, (III) liver surface
metastasis without mesothelium, scale bar = 400 μm.

2.4. Conclusion
In summary, nanoparticle delivery by IV administration is heavily hampered for the
treatment of PDAC due to the inherent dense stroma and tumor hypovascularity. IP
administration, on the other hand, could promote tumor accumulation of the
nanoparticles independent of the EPR effect by taking advantages of the broken
mesothelium on the surface of the tumors and metastasis. Specifically, our developed
nanoparticle system (PAMD-CHOL/siRNA, w/w 2) targets the tumors and even
penetrates into the central regions of the tumors in a manner independent of the tumor
blood vessels with minimal distribution to normal tissues. The effective peritoneal
retention and high local concentration of IP-injected nanoparticles also helped the
accumulation of nanoparticles in the tumor. The small particle size and optimized
hydrophobicity of the PAMD-CHOL nanoparticles possibly facilitated tumor penetration
of the nanoparticles [201]. PAMD-CHOL represents a promising delivery system for
PDAC therapy. Improved therapeutic efficacy is expected for the combination therapy
using PAMD-CHOL as the vector for the delivery of small RNAs.
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Chapter 3. Intraperitoneal triple combination nanotherapy to treat PDAC
3.1. Introduction
After decades of effort to develop better therapeutic approaches for PDAC,
conventional chemotherapy regimens offer at best only modest benefits [60]. The
failure of the current PDAC treatments has been in part due to their focus on cancer
cells without sufficient attention to the role of tumor stroma in PDAC progression.
Dense desmoplastic stroma is one of the hallmarks of PDAC [202]. Activated PSCs
are a key driver of desmoplasia via their production of ECM components. Intricate
PDAC stroma crosstalk regulates tumor cell growth, invasion, metastasis, and immune
escape through tumor–stroma interactions [203, 204]. Moreover, the nearly
impenetrable desmoplastic stroma severely hampers the conventional vascular
delivery of therapeutics into tumors, which further contributes to the treatment failure
[205]. Depletion of stromal desmoplasia has been reported to improve PDAC therapy
[206, 207]. However, some preclinical and clinical studies raise concerns that
extensive stromal depletion in PDAC may promote tumor progression, metastasis, and
reduce survival because of the elimination of critical stromal components needed for
tissue homoeostasis [195, 204, 208]. Nevertheless, due to the key role of stroma in
PDAC, targeting of cancer cells, stroma, and cancer cell-stroma interactions is a
promising approach for the development of improved therapies.
Hypoxia is a prominent feature of PDAC microenvironment caused by poor
perfusion and high oxygen demanded due to the unmet need of the cancer cell
proliferation, which plays a pivotal role in many aspects of the tumor progression [209].
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Hypoxia signaling is regulated by the HIFs, and concomitantly affects both cancer cells
and tumor stroma. Hypoxia stimulates PSCs to induce desmoplastic reactions [210,
211], and the desmoplasia further reinforces hypoxia, suggesting a positive feedback
loop between the two [212]. This interdependent relation promotes the aggressiveness
of PDAC and resistance to chemotherapy. It is also reported that the hypoxia signaling
would induce EMT and the formation of invadopodia, facilitating invasion and
metastasis [209]. MiRNAs are regulated by hypoxia through the HIF pathway. MiR-210
is one of the predominantly upregulated miRNAs induced by hypoxia [213, 214]. It
regulates multiple related signaling pathways needed for better adaptation of the cells
to the severe hypoxic environment [215]. PSCs can also induce miR-210 expression
in PDAC cells [216]. The overexpression of miR-210 alters multiple mRNA transcription
profile and appears to regulate cancer cell proliferation, apoptosis, and metastasis [217,
218]. Silencing of miR-210 with miRNA inhibitor (anti-miR) is a promising strategy to
modulate PDAC microenvironment to suppress tumor progression.
Mutations of KRAS act as key drivers of the tumor initiation, progression, and
metastasis [219, 220]. Inhibition of the oncogenic KRAS with genetic manipulation
inhibits PDAC progression in mice [221]. However, there are no effective smallmolecule KRAS inhibitors available [222]. Small interfering RNA targeting KRASG12D is
an effective alternative to small-molecule KRAS inhibitors and its use has been shown
to improve overall survival in mouse models of PDAC [165, 223].
Moreover, the chemokine receptor CXCR4 and its primary ligand CXCL12
regulate cancer development through tumor-stroma interactions. CXCL12 is secreted
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by activated PSCs and can specifically bind to CXCR4 on cancer cells to activate
multiple intracellular signaling pathways to promote migration and invasion of cancer
cells [224]. CXCR4/CXCL12 also facilitates cancer immune invasion by decreasing
cytotoxic CD8+ T-lymphocyte infiltration in tumors [144, 225]. Inhibitors targeting the
CXCR4/CXCL12 axis emerged as an effective approach to block tumor-stroma
interactions and demonstrated the therapeutic effect in PDAC through inhibition of
metastasis and augmentation of T cell immunotherapy [119, 144, 226].
Despite the strong biological rationale for the combined CXCR4/miR210/siKRASG12D therapy of PDAC, such efforts have been severely limited by the
physical barriers posed by the PDAC desmoplasia. We have proposed to take
advantage of the benefits of IP delivery for treating PDAC as described in Chapter 2
and to use the local delivery of triple combination nanotherapy using PAMD-CHOL as
the delivery vector. Due to the critical roles of miR-210, KRASG12D, and CXCR4 in
PDAC, together with the improved delivery by IP administration, we hypothesized that
combining silencing of miR-210/KRASG12D and blockade of CXCR4 would
cooperatively enhance the PDAC therapy through PSC inhibition, targeting cancer
cells, and inhibiting tumor-stroma interactions in pancreatic tumors (Scheme 3.1). To
test this hypothesis, we prepared PAMD-CHOL nanoparticles co-loaded with anti-miR210 and siKRASG12D, studied the efficacy of the triple-functional nanoparticles in
pancreatic cancer cells, and evaluated the therapeutic outcomes of the treatment in a
murine orthotopic PDAC model.
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Scheme 3.1. Proposed mechanism of the EPR-independent delivery of miRNA/siRNA
nanotherapy in pancreatic cancer treatment. IP administration delivers PAMD-CHOL
nanoparticles to orthotopic pancreatic tumor in an EPR-independent manner. PAMDCHOL nanoparticles effectively retain in peritoneal cavity, then specifically localize to
peritoneal tumor lacking surface mesothelium, and finally penetrate deep into tumor.
The nanoparticles modulate desmoplastic stroma, reduce immune suppression and
inhibit metastasis through simultaneously inactivating PSCs, inhibiting cancer cells and
blocking cancer-stroma interaction.
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3.2. Materials and methods
3.2.1. Materials
PBS, DMEM, FBS, trypsin, penicillin, and streptomycin were purchased from
Thermo Scientific (Waltham, MA). miR-210-3p-Hairpin Inhibitor (anti-miR-210, mature
miRNA sequence: CUGUGCGUGUGACAGCGGCUGA), negative control miRNA
inhibitor

(anti-miR-NC,

mature

miRNA

sequence:

UCACAACCUCCUAGAAAGAGUAGA), siRNA targeting KRASG12D (siKRASG12D,
sense sequence, 5′-GUUGGAGCUGAUGGCGUAGdTdT-3′) and negative control
siRNA (siNC, sense sequence, 5′-UCACAACCUCCUAGAAAGAGUAGA-3′) were
obtained from Dharmacon (Lafayette, CO). Average Mw of anti-miRNA is 18,500 g/mol.
Average Mw of siRNA is 13,300 g/mol. Real-time polymerase chain reaction (RT-PCR)
primers and Anti-CD8 antibody (Catalog #: 14-0808-80) were from Invitrogen
(Carlsbad, CA). APC conjugated anti-CXCR4 antibody (Catalog #: 560936) was from
BD Biosciences (San Jose, CA). Anti-αSAM (Catalog #: ab5694), anti-CD31 (Catalog
#: ab28364), anti-CXCR4 (Catalog #: ab124824) and anti-ALDH1A1 (Catalog #:
ab227948) antibodies were bought from Abcam (Cambridge, MA). Anti-CD206
antibody (Catalog #: MCA2235) was from Bio-Rad (Hercules, CA). Anti-Kras antibody
(Catalog #: sc-30) was from SCBT (Dallas. TX). Collagen type I antibody (Catalog #:
14695-1-AP) was from Proteintech. Anti-CD44 antibody (Catalog #: 103001) was from
BioLegend (San Diego, CA). Other reagents were provided by Fisher Scientific and
used as received unless stated otherwise.
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3.2.2. Methods
3.2.2.1. Preparation and characterization of nanoparticles
PAMD-CHOL/(anti-miR+siRNA) nanoparticles were prepared by mixing a
predetermined volume of PAMD-CHOL with an anti-miR and siRNA equal molar
solution (20 μM in pH 7.4 HEPES) and vortexing for 10 s. The mixture was set at room
temperature for 20 min before use.
Agarose gel electrophoresis was performed to test the ability of PAMD-CHOL to
condense anti-miR and siRNA. Nanoparticles at various polycation-to-(antimiR+siRNA) weight ratios were loaded in the gel (0.5 μg/mL ethidium bromide) and
ran in 0.5 × Tris/Borate/EDTA buffer for 15 min (100 V). The gels were observed with
KODAK Gel Logic 100 imaging system. Dynamic light scattering (DLS) was used to
measure the hydrodynamic diameter and zeta potential of the nanoparticles using
ZEN3600 Zetasizer Nano-ZS (Malvern Instruments Ltd., Massachusetts, USA).
Nanoparticle morphology was visualized using TEM (Tecnai G2 Spirit, FEI Company,
USA) with NanoVan® negative staining (Nanoprobes, USA) and MultiMode AFM
NanoScope IV system (Bruker Instruments, Santa Barbara, CA) operating in tapping
mode.
For release ability test, heparin displacement assay was applied to analyze antimiR and siRNA release from nanoparticles. Nanoparticles (w/w = 2) were incubated
with heparin solution for 30 min, then assayed by gel electrophoresis. For the enzyme
stability test, free anti-miR+siRNA solution and nanoparticles were incubated with FBS
(50% v/v), RNase I (2 U/μL), mouse serum (50%) and KPC mouse ascites (50%) at
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37 °C, respectively. The samples were collected at predetermined time points, treated
with heparin, and analyzed by gel electrophoresis. For protein binding stability,
polyplexes formed by PAMD-CHOL and PEI (w/w 2) were incubated with 10% mouse
serum or ascites at 37 °C for 1 h. Then the samples were centrifuged at 14,000 g for
1 h at 4 °C. The supernatant was discarded while the pellet was washed with PBS and
resuspended in 2% SDS and 4% Triton X-100 lysis buffer. Samples were centrifuged
again, and the supernatant solutions were collected for protein concentration analysis
by BCA assay. Individual proteins in the supernatant were further analyzed by SDSPAGE. 10% mouse serum or ascites were loaded as controls.
3.2.2.2. Analysis of CXCR4 expression on the cell surface
Cells were trypsinized, washed and incubated with allophycocyanin (APC) labeled
CXCR4 antibody (BD Biosciences, CA) for 1 h at 4 °C. The isotype-matched antibody
was employed to assess the background fluorescence. Cells were subjected to a
FACS Calibur (BD Bioscience, Bedford, MA) and results were analyzed by FlowJo
software (Tree Star Inc., OR).
3.2.2.3. Cytotoxicity
Cytotoxicity of PAMD-CHOL and PEI were tested by CellTiter-Blue Cell Viability
Assay. Cells were treated with 100 μL of polymer solutions with various concentrations
in culture medium for 24 h. The medium was then replaced by a mixture of 100 μL
media and 20 μL of CellTiter-Blue reagent. The fluorescence [F] (Ex = 560 nm, Em =
590 nm) was measured using Microplate Reader (Molecular Devices, CA) after 2 h
incubation. The relative cell viability (%) was expressed as [F]sample/[F]untreated ×
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100%. The IC50 values (50% cell growth inhibition) were obtained from a doseresponse analysis in GraphPad Prism.
3.2.2.4. Transwell migration assay
Cells were trypsinized, washed with PBS and resuspended in medium without
serum. Cells pretreated with tested compounds for 15 min or without treatment were
added in the cell culture inserts (8.0 μm pores, BD Biosciences) in 300 μL of serumfree medium (3 × 105 cells per insert). The lower transwell chamber was filled with 600
μL of serum-free medium containing 20 nM CXCL12. After 20 h incubation, removal of
cells in the top chamber was done using cotton swabs. Migrated cells were fixed,
stained with 0.2% Crystal Violet and observed under EVOS xl microscope. The results
were calculated as the percentage of migrated cells relative to PBS-treated
cells/imaging field ± SD (n = 3).
3.2.2.5. Cellular uptake and intracellular trafficking
Cells were seeded in 12-well plates 24 h before treatment. Cells were treated by
nanoparticles prepared with AF647-PAMD-CHOL and FAM-siRNA (w/w =2, 100 nM
FAM-siRNA) for 4 h in the presence of FBS. Cells were washed by PBS, detached with
trypsin and analyzed on a FACS Calibur (BD Bioscience, Bedford, MA). Subcellular
distribution of nanoparticles was observed by confocal microscopy. Cells were seeded
on a 20 mm glass-bottom culture dish (Nest) 24 h before treatment. AF647-PAMDCHOL/FAM-siRNA nanoparticles were added and incubated for 4 h. Cells were
washed, stained with Hoechst 33258 and visualized under an LSM 800 Laser
Scanning Microscope (Zeiss, Jena, Germany). To observe the endo/lysosomal release,
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cells were treated by nanoparticles for 2 h or 6 h. Then, cells were stained with
LysoTracker Red DND-99 (Life Technology, USA) and visualized with a confocal
microscope.
3.2.2.6. Tumor penetration in multicellular tumor spheroids
KPC8060 cells were seeded in ultra-low attachment 96 well plates at a density of
1 × 104 cells per well. The spheroid diameter reached about 400 μm after culturing for
7 days. AF647-PAMD-CHOL/FAM-siRNA nanoparticles were incubated with spheroids
for 12 h. Spheroids were washed with PBS, fixed with 4% paraformaldehyde and
observed with a confocal microscope (z-stack with 10 μm intervals). Fluorescence
images were transformed to surface plots by ImageJ software. The spheroids were
also trypsinized to single-cell suspension for flow cytometry analysis.
3.2.2.7. Quantitative real-time polymerase chain reaction (qRT-PCR)
Cells were incubated with PAMD-CHOL nanoparticles (anti-miR 50 nM, siRNA 50
nM) for 48 h in the presence of FBS. Total RNA was extracted from cultured cells using
the mirVana miRNA Isolation Kit (Ambion, USA). MiRNA level was measured by
TaqMan qRT-PCR. RNA (10 ng) was converted to cDNA by TaqMan miRNA reverse
transcription kit (Applied Biosystems) and primers for miR-210 or Z30 (internal control)
(Applied Biosystems, CA). PCR reaction was conducted on Rotor-Gene Q (QIAGEN)
using TaqMan Universal Master Mix and primers for miR-210 or Z30 (Applied
Biosystems). Expression of KRASG12D was quantified using SYBR Green RT-PCR.
RNA (0.5 μg) was reverse transcribed to cDNA with QuantiTect reverse transcription
kit (Qiagen). PCR reaction was performed on Rotor-Gene Q (QIAGEN) using the
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QuantiFast SYBR Green PCR kit (Qiagen). The GAPDH primer assay (QIAGEN) was
used following the manufacturers protocol.

KRAS G12D primer (forward 5′-

CGCAGACTTACTTCCCCGGC; reverse, 5′-CGCTCAATTCCTCAACCACG) was
used. Relative miRNA or mRNA levels were calculated according to the comparative
threshold value (Ct) method.
3.2.2.8. Apoptosis assay by DAPI staining
Cells were treated with nanoparticles (50 nM anti-miR, 50 nM siRNA) for 48 h.
Cells were stained with 2 μg/mL DAPI and observed under EVOS xl fluorescence
microscope (Thermo, USA). Apoptotic nuclei with condensed and fragmented
morphology were counted and presented as a percentage of total nuclei per
observation field.
3.2.2.9. Cell killing assay
Cytotoxicity of the nanoparticles was evaluated by CellTiter-Blue assay. Cells
were treated with nanoparticles (50 nM anti-miR, 50 nM siRNA) for 48 h. The medium
was then replaced by a mixture of 100 μL media and 20 μL of CellTiter-Blue reagent.
After 2 h incubation, fluorescence [F] (Ex = 560 nm, Em = 590 nm) was measured
using Microplate Reader (Molecular Devices, CA). The relative cell viability (%) was
expressed as [F]sample/[F]untreated × 100%.
3.2.2.10. Colony formation assay
Cells were treated with nanoparticles (50 nM anti-miR, 50 nM siRNA) for 4 h. Cells
were seeded to 12-well plates (KPC8060 cells 200/well, COLO357 cells 600/well).
After growth for 12 days, cells were fixed, stained with Crystal Violet (0.2%), washed
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with water and photographed. Colony number in each well was counted.
3.2.2.11. Stromal markers immunofluorescence staining of PSCs
Human PSCs were seeded in 8-well chambered cover glass (Thermo Fisher) and
treated with nanoparticles for 48 h. After that, cells were fixed in 4% paraformaldehyde
for 15 min, permeabilized in 0.2% Triton X-100 for 1 h and blocked with 5% bovine
serum for 30 min. α-SMA or Collagen I primary antibodies were diluted in 1% BSA and
incubated with cells at 4 °C overnight, respectively. Cells were washed several times
with PBS after the primary antibody incubation and changed with anti-rabbit IgG Alexa
Fluor® 488 secondary antibody (Thermo Fisher) for 1 h. The nuclei were
counterstained with Hoechst 33342 for 15 min. Images were acquired using the Zeiss
LSM 800 confocal microscope.
3.2.2.12. Antitumor activity in vivo
Animal protocols have been approved by the University of Nebraska Medical
Center Institutional Animal Care and Use Committee. Orthotopic KPC-derived
pancreatic cancer model was established by injection of 2.5 × 104 of KPC8060 cells
into the tail of the pancreas (details described in Chapter 2, Methods 2.2.2.5). Mice
were randomly assigned to 5 groups (n = 5) and IP injected with PBS, PAMDCHOL/(anti-miR-NC+siNC), PAMD-CHOL/(anti-miR-210+siNC), PAMD-CHOL/(antimiR-NC+siKRASG12D), and PAMD-CHOL/(anti-miR-210+siKRASG12D), respectively.
PAMD-CHOL/(anti-miRNA+siRNA) nanoparticles (5 mg/kg PAMD-CHOL) were
injected at days 14, 16, 18, 20, 22, 24 and 26 post tumor-implantation. Mouse body
weight was recorded during treatment. On days 28, blood was harvested from retro-
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orbital venous plexus of the mouse for whole blood analysis and serum biochemistry
test. Mice were sacrificed, and primary tumor weight and metastatic sites were
evaluated in each experimental group. Total RNA in the tumor was isolated using
mirVana™ miRNA Isolation Kit. Protein was also harvested from tumor tissues using
RIPA Lysis buffer. Tumors and major organs were fixed in 4% paraformaldehyde and
sectioned for histochemical analysis. Survival analysis was performed on mice with
the same treatment method but with 9 mice per group.
3.2.2.13. Western blot
Protein concentration was measured by BCA kit (Promega, USA). The protein
solution was denatured, loaded to 10% SDS-PAGE electrophoresis gel (running 2 h at
120 V) and transferred to a nitrocellulose membrane (running 1 h at 300 mA). The
membrane was blocked, incubated with primary antibody overnight at 4 °C, washed
and incubated with IgG HRP-linked antibody (Cell Signaling Technology, USA). Finally,
membranes were visualized using Pierce™ ECL Western Blotting Substrate (Thermo
Scientific, USA). Western blot bands were quantified with ImageJ software.
3.2.2.14. Histochemical analysis
Tumor or organ sections were analyzed with H&E and Masson’s trichrome staining
(collagen coverage percentage in each observation field was quantified by ImageJ
software). Antigen retrieval was conducted. Ki-67 immunohistochemical staining was
performed to study the proliferation of tumor cells. For immunofluorescence staining,
tumor slides were treated with endogenous peroxidase inhibitor, incubated with
primary antibody at 37 °C for 32 mins, incubated with HRP-conjugated secondary
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antibody at 37 °C for 32 mins, and incubated with Discovery FITC Kit (Roche). Sections
were also counterstained with DAPI for nucleus visualization. Immunohistochemistry
images were taken on the EVOS xl microscope (Thermo, USA). Immunofluorescence
slides were mounted with antifade reagent and observed using a confocal microscope
(LSM 800).
3.2.2.15. Blood chemistry analysis
Blood was withdrawn in heparin tubes and analyzed using Vetscan VS (Abaxis).
Creatinine, blood urea nitrogen (BUN), alanine transaminase (ALT) and aspartate
transaminase (AST) were measured by assay kit (Bioassay Systems, CA, USA)
according to the protocol.
3.2.2.16. Statistical analysis
Results are presented as mean ± SD. ANOVA was used to analyze differences
among multiple groups followed by Tukey’s multiple comparison test. Students t -test
was used to analyze the statistical significance between the two groups. P < 0.05 was
considered as a minimal level of significance. All statistical analysis was performed
with GraphPad Prism v5.
3.3. Results and discussion
3.3.1. Characterization of PAMD-CHOL/(anti-miR + siRNA) nanoparticles
PAMD-CHOL polymer used in this study was from the same batch of the polymer
synthesized and characterized in Chapter 2. The ability of PAMD-CHOL to form
nanoparticles and encapsulate both anti-miR and siRNA was evaluated with agarose
gel electrophoresis. The nanoparticles were prepared by mixing various amounts of
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PAMD-CHOL with a mixture of anti-miR/siRNA containing equal molar concentrations
of the two RNAs. PAMD-CHOL fully condensed the anti-miR/siRNA mixture at and
above PAMD-CHOL/(anti-miR+siRNA) w/w ratios of 2 (Figure 3.1A). The nanoparticles
were narrowly distributed with an average hydrodynamic size of 57 nm and a positive
zeta-potential of 19.5 mV according to dynamic light scattering measurement (Figure
3.1B, C). The nanoparticles presented as uniform particles with a mostly spherical
morphology based on observation using transmission electron microscopy (TEM) and
atomic force microscopy (AFM) (Figure 3.1D, E).

Figure 3.1. Characterization of the PAMD-CHOL/ (anti-miR + siRNA) nanoparticles.
(A) Analysis of the condensation of anti-miR and siRNA by PAMD-CHOL using agarose
gel electrophoresis. (B, C) Measurement of hydrodynamic size (B) and zeta-potential
(C) of PAMD-CHOL/(anti-miR+siRNA) nanoparticles (w/w = 2) by dynamic light
scattering. (D, E) TEM (D) and AFM (E) images of PAMD-CHOL/(anti-miR+siRNA)
nanoparticles (w/w = 2).
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Heparin displacement assay was used to evaluate the release of anti-miR and
siRNA from the nanoparticles. The anti-miR and siRNA combination was completely
released from the nanoparticles at the heparin concentration above 160 μg/mL (Figure
3.2A). Since poor stability in the presence of serum and nucleases may limit the in vivo
application of RNA, the stabilities of the nanoparticles against FBS and RNase I were
analyzed using gel electrophoresis. In comparison with a mixture of naked anti-miR
and siRNA, PAMD-CHOL nanoparticles improved the stability of anti-miR/siRNA
against both serum and RNase I degradation (Figure 3.2B, C).
Protein binding and stability in biological media are important factors in
determining the in vivo fate of nanoparticles [227]. Before in vivo analysis of the
nanoparticles, we studied their protein binding and stability in ascites and serum
obtained from orthotopic PDAC mice, mimicking the in vivo environments the
nanoparticles may encountered. The protein binding of the PAMD-CHOL nanoparticles
reversed the surface charge to negative values (Figure 3.2D). PAMD-CHOL
nanoparticles showed pronounced protein binding in both ascites and mouse serum.
However, the extent of protein binding was much lower than in the case of control PEI
particles (Figure 3.2E, F). Importantly, PAMD-CHOL nanoparticles showed no signs of
disassembly or aggregation upon protein binding. The nanoparticles also retained
colloidal stability with sub-100 nm size (Figure 3.2G) and protected anti-miR/siRNA
against ascites and serum degradation (Figure 3.2H, I).
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Figure 3.2. Stability of the PAMD-CHOL/ (anti-miR + siRNA) nanoparticles. (A)
Heparin induced anti-miR/siRNA release from PCX/(anti-miR+siRNA) nanoparticles
(w/w=2) with increasing concentration of heparin. (B, C) Serum (B) and RNase I (C)
stability assays of naked anti-miR/siRNA and PCX/(anti-miR+siRNA) nanoparticles.
Agarose gel electrophoresis of samples after treatment with serum or RNase I for
different time intervals at 37 °C. (D) Surface charge of nanoparticles after incubation
with different percentage of ascites or mouse serum at 37 °C for 1 h. (E, F) Protein
binding to nanoparticles was determined by SDS-PAGE (E) and BCA protein assay (F)
(wprotein/wnanoparticles/protein (mg)/nanoparticles (mg). Nanoparticles were incubated with
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ascites obtained from tumor-bearing mice or mouse serum at 37 °C for 1 h. Data are
shown as mean ± SD (n = 3). (G) TEM observation of nanoparticles after incubation
with ascites or mouse serum at 37 °C for 24 h. Scale bar = 500 nm. (H, I) Stability of
naked anti-miR/siRNA and PCX/(anti-miR+siRNA) nanoparticles upon incubation with
ascites (H) or mouse serum (I). Agarose gel electrophoresis of samples after treatment
with ascites or mouse serum (50% v/v).

3.3.2. Inhibition of PDAC cell migration in vitro
Prior to examining the delivery efficacy of the nanoparticles, we evaluated the
ability of PAMD-CHOL to inhibit migration of mouse and human PDAC cells. Surface
expression of CXCR4 receptor was first confirmed in murine KPC8060 cells (32.7%
CXCR4+) and human COLO357 cells (55.6% CXCR4+) used in this study (Figure 3.3A).
The toxicities of the polymers (PAMD-CHOL and PEI) were also evaluated (Figure 3.3B)
in both cell lines. To minimize the potential effect of polymer cytotoxicity on cell
migration, we used 2 μg/mL as a safe PAMD-CHOL and PEI concentration. AMD3100
(300 nM) was used as a positive control. CXCL12 induced migration of both KPC8060
and COLO357 cells. PAMD-CHOL and AMD3100 showed nearly complete inhibition
of the migration of KPC8060 cells at the tested concentrations. Both PAMD-CHOL and
AMD3100 also exhibited strong inhibitory activity in the human COLO357 cells. Control
PEI failed to inhibit migration of either of the used cell lines (Figure 3.3C).
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Figure 3.3. CXCR4 overexpression of PDAC cells and inhibition of CXCL12-induced
cell migration of PAMD-CHOL. (A) CXCR4 expression on pancreatic cancer cells
measured by flow cytometry. The percent of CXCR4-positive cells and mean
fluorescence intensity (MFI) were analyzed using FlowJo software. (B) Cytotoxicity of
polymers in pancreatic cancer cells after incubation for 24 h. IC50 values calculated
from the dose–response curves. Data are shown as mean ± SD (n = 3). (C, D)
Inhibition of CXCL12-induced PDAC cell migration. KPC8060 and COLO357 cells
were treated with AMD3100 (300 nM), PAMD-CHOL (2 µg/mL) or PEI (2 µg/mL) and
cultured in a transwell membrane insert (3 × 105 cells) with CXCL12 (20 nM) as
chemoattractant. Migrated cells were observed (C) and counted (D) under a
microscope. Scale bar, 200 μm. Data are shown as mean ± SD (n = 3). ***P < 0.001.
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3.3.3. Delivery of miRNA/siRNA combination in PDAC cells in vitro
We next examined the efficacy of the nanoparticle delivery to PDAC cells in vitro.
Since anti-miR and siRNA share similar physiochemical properties, we prepared the
PAMD-CHOL nanoparticles using only the siRNA. Fluorescently labeled PAMD-CHOL
(AF647-PAMD-CHOL) and siRNA (FAM-siRNA) were used in this study to visualize
the uptake and intracellular distribution in KPC8060 and COLO357 cells. Both AF647PAMD-CHOL (red) and FAM-siRNA (green) were internalized in the cells,
demonstrating effective uptake of the nanoparticles (Figure 3.4A). Flow cytometry
analysis confirmed that 86% of the KPC8060 cells and 87% of the COLO357 cells
internalized both PAMD-CHOL and siRNA (Figure 3.4B). Endosomal escape of the
nanoparticles was studied in the two cell lines by staining endo/lysosomes with
LysoTrackerRed. The fluorescence of the FAM-siRNA (green) was found mostly
colocalized with endolysosomes (red) after incubation for 2 h. After 6 h, FAM-siRNA
localized predominantly in the cytoplasm with only a limited extent of co-localization
with the endo/lysosomes (Figure 3.4C). This result confirmed effective endosomal
escape of the nanoparticles in PDAC cells, which can promote the subsequent
transfection efficacy.
Lastly, we analyzed the penetration of the PAMD-CHOL nanoparticles into 3D
multicellular tumor spheroids. The multicellular spheroids were made by plating 10,000
KPC8060 cells per well into the ultra-low attachment 96 well plates and cultured for 7
days when the spheroids diameter reached ~400 μm. The penetration was evaluated
by measuring the fluorescence of FAM-siRNA with confocal microscopy of the
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spheroids and flow cytometry of single cell suspension prepared from the spheroids.
PAMD-CHOL/FAM-siRNA nanoparticles showed effective tumor-penetrating ability as
suggested by the observed internalization in 76% of the cells in the tumor spheroids
(Figure 3.4D).
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Figure 3.4. Cellular uptake and intracellular trafficking of PAMD-CHOL nanoparticles
in KPC8060 and COLO357 cells. (A) Confocal microscopy observation of KPC8060

74

and

COLO357

cells

after

treatment

with

AF647-PAMD-CHOL/FAM-siRNA

nanoparticles for 4 h. Scale bar, 20 μm. (B) Flow cytometry analysis of KPC8060 and
COLO357 cells treated with AF647-PCX/FAM-siRNA for 4 h. (C) Confocal microscopy
observation of intracellular trafficking of PAMD-CHOL/FAM-siRNA nanoparticles in
KPC8060 and COLO357 cells after 2 h or 6 h of incubation. Scale bar, 20 μm. (D)
Surface plot of KPC8060 multicellular spheroids after treatment with free FAM-siRNA
or PAMD-CHOL/FAM-siRNA for 12 h. Flow cytometry analysis of KPC8060 cells
digested from multicellular spheroids.

3.3.4. Transfection efficacy of the PAMD-CHOL nanoparticles co-delivering antimiR-210 and siKRASG12D in PDAC cells and PSCs in vitro
After successful cellular uptake and endosomal escape in PDAC cells, the
released therapeutic anti-miR and siRNA are ready to play the role in silencing target
miRNA and mRNA, respectively. The efficacy of the delivery was assessed from the
silencing of the target RNA using nanoparticles co-loaded with anti-miR-210 and
siKRASG12D in the mouse KPC8060 and human COLO357 PDAC cells. Control
nanoparticles with negative controls anti-miR-NC and siNC were also used. PDAC
cells were treated with the PAMD-CHOL nanoparticles and expression of miR-210, and
KRASG12D mRNA was measured using qRT-PCR. Treatment with PAMD-CHOL/(antimiR-210+siNC) nanoparticles significantly downregulated the miR-210 expression in
both cell lines (~51% decrease in KPC8060 cells; ~70% decrease in COLO357 cells)
but did not affect KRAS expression (Figure 3.5A). Likewise, PAMD-CHOL/(anti-miR-
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NC+siKRASG12D) nanoparticles reduced KRASG12D mRNA levels (~40% decrease in
KPC8060 cells; ~20% decrease in COLO357 cells) but did not affect miR-210
expression

(Figure

3.5B).

Only

treatment

with

PAMD-CHOL/(anti-miR-

210+siKRASG12D) nanoparticles downregulated both miR-210 and KRASG12D mRNA
levels (Figure 3.5A, B). Similarly, inhibition of CXCR4 alone (PAMD-CHOL/(anti-miRNC+siNC)) did not affect the expression of either miR-210 or KRAS.
Next, we studied the anticancer activity (i.e. cell killing) of the nanoparticles in
PDAC cells. Effect of the nanoparticles on PDAC cell apoptosis was analyzed by
staining the cells with DAPI and evaluating their nuclear morphology. Upon treatment
with PAMD-CHOL/(anti-miR-210+siKRASG12D), more than 40% of the KPC8060 cells
were apoptotic. Nanoparticles with only single active RNA (PAMD-CHOL/(anti-miR210+siNC) and PAMD-CHOL/(anti-miR-NC+siKRASG12D) only induced apoptosis in ~9%
and ~14% cells, respectively. Similar combined pro-apoptotic effect of the PAMDCHOL/(anti-miR-210+siKRASG12D) nanoparticles was also found in the human
COLO357 cells (Figure 3.5C). These findings were validated by a cell viability assay
(Figure 3.5D). PAMD-CHOL/(anti-miR-210+siKRASG12D) nanoparticles exhibited
significantly enhanced cell killing activity (∼66% in KPC8060 cells; ∼60% in COLO357

cells) than PAMD-CHOL/(anti-miR-210+siNC) nanoparticles (∼30% in both cells) and

PAMD-CHOL/(anti-miR-NC+siKRASG12D) nanoparticles (∼45% in KPC8060 cells; ∼37%
in COLO357 cells).

Colony formation assay was used last to evaluate the tumorigenicity of cancer
cells after treatment with the nanoparticles (Figure 3.5E). Treatment with PAMD-
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CHOL/(anti-miR-210+siKRASG12D) reduced colony formation in PDAC cells by more
than 70%. This inhibition effect was significantly higher than that of PAMD-CHOL/(antimiR-210+siNC) nanoparticles and PAMD-CHOL/(anti-miR-NC+siKRASG12D) in both
cell lines. Overall, results from the in vitro anticancer activity studies confirmed the
combined

anticancer

activity

of

PAMD-CHOL/(anti-miR-210+siKRASG12D)

nanoparticles in pancreatic cancer cells through downregulation of both miR-210 and
KRASG12D, while indicating no significant cytotoxic effect of the CXCR4 inhibition.

Figure 3.5. Transfection efficacy of the PAMD-CHOL nanoparticles in PDAC cells in
vitro. (A) Levels of miR-210 in KPC8060 and COLO357 cells after treatment with
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PAMD-CHOL nanoparticles for 48 h. (B) Levels of KRASG12D mRNA in KPC8060 and
COLO357 cells after treatment with PAMD-CHOL nanoparticles for 48 h. (C) Cell
apoptosis assay by DAPI staining. Percent of apoptotic nuclei were calculated by
dividing apoptotic nuclei by total nuclei per observation field under an EVOS xl
microscope. (D) Cell viability assay by CellTiterBlue after PAMD-CHOL nanoparticles
treatment for 48 h. (E) Colony formation assay of cells after treatment by nanoparticles.
Nanoparticles containing 50 nM anti-miR, 50 nM siRNA are used for all the studies.
Data are shown as mean ± SD (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001.

MiR-210 overexpression can convert healthy fibroblasts into CAFs [228]. PSCs,
as a subset of CFAs are expected to be inactivated by silencing of miR-210 and thus
to favorably modulate the tumor microenvironment. We studied the treatment effect on
cultured primary human PSCs by qRT-PCR and immunofluorescence (IF) staining of
fibrosis markers. As shown in Figure 3.6A, significant downregulation of miR-210
expression was only observed in PSCs cells after treatment with PAMD-CHOL/(antimiR-210+siNC) and PAMD-CHOL/(anti-miR-210+siKRASG12D) nanoparticles. As
shown in Figure 3.6B, activated PSCs (untreated G1 group) expressed high levels of
α-SMA and collagen I, while the silencing of miR-210 by PAMD-CHOL/(anti-miR210+siNC) nanoparticles and PAMD-CHOL/(anti-miR-210+siKRASG12D) nanoparticles
significantly decreased the expression of both α-SMA and collagen I in PSCs,
indicating inactivation of PSCs. Delivery of siKRASG12D failed to inactivate PSCs.
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Figure 3.6. Reversal of activated primary human PSCs by downregulation of miR-210
with PAMD-CHOL nanoparticles in vitro. (A) Levels of miR-210 in PSCs cells after
treatment with PAMD-CHOL nanoparticles for 48 h. (B) Immunofluorescence staining
of α-SMA and collagen I in primary human PSCs after treatment with PAMD-CHOL
nanoparticles (50 nM anti-miR, 50 nM siRNA) for 48 h. The relative expression levels
(mean fluorescence intensity) of fibrosis marker was quantified using Image J software.
Data are shown as mean ± SD (n = 3). *P < 0.05, **P < 0.01.

3.3.5. Inhibition of orthotopic PDAC mouse tumor growth by IP administration
of the PAMD-CHOL nanoparticles
As shown above, IP administration has greatly improved the tumor accumulation
and penetration of the PAMD-CHOL nanoparticles in orthotopic PDAC tumors
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compared with IV administration. Treatment efficacy of the IP-administered
nanoparticles delivering therapeutic miR-210 and siKRASG12D was tested in the mice
bearing the KPC8060 orthotopic pancreatic tumors. The treatments were given every
other day started on day 14 post- KPC8060 cell implantation for a total of 7 doses
(Figure 3.7A). No changes were observed in the mouse body weight during treatment,
which confirmed that the PAMD-CHOL nanoparticles caused no gross toxicity in the
animals (Figure 3.7B). After treatment, primary pancreatic tumors were harvested from
sacrificed mice for analysis. In comparison with the PBS group, treatment with PAMDCHOL/(anti-miR-NC+siNC) nanoparticles showed a negligible effect on the primary
tumor growth, confirming that CXCR4 inhibition by PAMD-CHOL alone has no
significant effect on tumor cell proliferation. Both PAMD-CHOL/(anti-miR-210+siNC)
and PAMD-CHOL/(anti-miR-NC+siKRASG12D) inhibited primary tumor growth by ~43%
and ~47%. The combination PAMD-CHOL/(anti-miR-210+siKRASG12D) nanoparticles
showed the best activity with 60% primary tumor growth inhibition (Figure 3.7C).
Successful delivery of the two therapeutic RNAs was confirmed from the levels of miR210, and KRASG12D quantified by qRT-PCR and Western blot in the tumors of treated
mice. IP treatment with the PAMD-CHOL/(anti-miR-210+siKRASG12D) resulted in 76%
downregulation of miR-210 and 74% silencing of the KRASG12D expression in the
isolated tumors (Figure 3.7D, E).
Ki-67 immunohistochemical tumor staining was performed to study the
antiproliferative activity of the nanoparticles (Figure 3.7F). The PAMD-CHOL/(antimiR-210+siKRASG12D) treatment showed the best antiproliferative activity, with only 26%
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of Ki-67+ cells. In comparison, silencing of miR-210 or KRASG12D alone resulted in
modest

antiproliferative

activity.

PAMD-CHOL/(anti-miR-210+siKRASG12D)

nanoparticles also induced the greatest necrosis in the tumor based on H&E staining
(Figure 3.7G). These results confirm that the IP injection of the PAMD-CHOL
nanoparticles facilitates the delivery of both anti-miR and siRNA to target oncogenic
miR-210 and KRASG12D in orthotopic pancreatic tumors.

Figure 3.7. Inhibition of orthotopic PDAC mouse tumor growth by IP administration of
PAMD-CHOL nanoparticles. (A) Orthotopic tumor-bearing mice received multiple IP
injections of PAMD-CHOL/(anti-miR+siRNA) nanoparticles (5 mg/kg PAMD-CHOL,
1.25 mg/kg anti-miRNA, 1.25 mg/kg siRNA). (B) Relative mouse body weight (%)
during treatment. (C) The weight of the primary tumor from the mouse after treatment
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(n = 5). (D) Levels of miR-210 in tumors after treatment analyzed by qRT-PCR analysis
(n = 3). (E) Expression of KRAS12D in tumors after treatment analyzed by Western blot.
(F) Immunohistochemistry analysis of Ki-67 in tumors after treatment. Scale bar = 100
µm. Fifteen visual fields were randomly captured per each group for quantification. (G)
H&E staining of tumor sections after treatment with nanoparticles. Data are shown as
mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001.

3.3.6. PDAC TME modulation by PAMD-CHOL nanoparticles
TME modulation by the IP-delivered PAMD-CHOL nanoparticles was also
assessed. Histological analysis of fibrosis markers was performed to study the effect
of the PAMD-CHOL nanoparticles on tumor desmoplasia (Figure 3.8A). Control PAMDCHOL/(anti-miR-NC+siNC) nanoparticles reduced the activation of PSCs (~21% αSMA+) in comparison with PBS group (~30% α-SMA+). Silencing of miR-210 by PAMDCHOL/(anti-miR-210+siNC) nanoparticles (~11% α-SMA+) and PAMD-CHOL/(antimiR-210+siKRASG12D) nanoparticles (~9% α-SMA+) further significantly inhibited the
activation of PSCs. Silencing of siKRASG12D had no additional effect on the activation
status of PSCs in the tumors (~20% α-SMA+). These results confirmed a combined
effect of nanoparticles to inhibit the activation of PSCs.
Activated PSCs produce collagen which is the main component of PDAC ECM.
The combined PAMD-CHOL nanoparticles decreased collagen content in the tumors
to ~9% (percent of stained area quantified by ImageJ software) (Figure 3.8B). PAMDCHOL/(anti-miR-NC+siNC) nanoparticles (~16% collagen content) and miR-210
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downregulation (~9% collagen content) also significantly decreased collagen in tumor
compared with PBS (~24% collagen). This result is consistent with the inhibition of
activated

PSCs

and

confirms

that

PAMD-CHOL/(anti-miR-210+siKRASG12D)

nanoparticles cooperatively reduced activation of PSCs and extent of tumor fibrosis
through combined CXCR4 blockade and miR-210 silencing. Activated PSCs are also
a driver of angiogenesis [210, 229]. PAMD-CHOL/(anti-miR-210+siKRASG12D)
nanoparticles presented significant anti-angiogenic activity which was indicated by
reduced CD31+ blood vessel density in the tumors (Figure 3.8C).
Tumor stroma contributes to the establishment of an immunosuppressive TME in
PDAC. Modulation of tumor stroma represents a therapeutic approach to augment
immunotherapy [230]. However, the effect of depletion of tumor stroma on cancer
immune response remains controversial with both pro- and anti-tumorigenic roles. It
has even been reported that depletion of PSCs in the PDAC stroma enhanced
immunosuppression and promoted tumor progression through facilitating infiltration of
suppressive immune cells [204]. Considering the risk of stromal depletion on the
immune response, we analyzed the effect of the nanoparticle treatment on the tumor
immune microenvironment. Dense desmoplasia is a physical barrier to the infiltration
of cytotoxic T lymphocytes. As shown in Figure 3.8D, treatment with control PAMDCHOL/(anti-miR-NC+siNC) nanoparticles increased CD8+ T cell infiltration, which was
most likely due to their CXCR4 inhibitory effect exerted by PAMD-CHOL. Interestingly,
downregulation of miR-210 in the tumors also contributed to the enhanced infiltration
of CD8+ T cells. These results confirmed a combined effect of PAMD-CHOL/(anti-miR-
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210+siKRASG12D) nanoparticles on tumor-accumulation of CD8+ T cells. A recent study
confirmed that reduction of desmoplasia by CXCR4 blockade does indeed increase
the tumoral infiltration of T cells [231]. Importantly, our nanoparticles cooperatively
promoted tumor accumulation of CD8+ T cells possibly through a combination of
CXCR4 inhibition and miR-210 silencing to reduce desmoplasia. Moreover,
significantly decreased levels of suppressive M2 tumor-associated macrophages
(CD206+ M2 TAMs) were also observed in the tumors after nanoparticle treatment,
which we believe was again due to CXCR4 inhibition by PAMD-CHOL (Figure 3.8E).
This result demonstrated the effect of the PAMD-CHOL nanoparticles on modulation
of TAMs to reverse immunosuppressive tumor microenvironment. We also determined
the levels of intratumoral cytokines to study the effect of nanoparticles on the tumor
immunosuppressive microenvironment. Pro-inflammatory cytokines IFN-γ and TNF-α
are mainly secreted by cytotoxic T-cells and are involved in T-cell killing for tumor
suppression [232]. Treatment with nanoparticles significantly increased the secretion
of IFN-γ and TNF-α (Figure 3.8E, G), which further confirmed the immunostimulatory
effect of the nanoparticles.
Depletion of desmoplasia potentially induces cancer stem cell-like phenotype,
which possibly enhances tumorigenicity and decreases survival [204, 233]. Here, we
compared the stemness of the tumors after nanoparticle treatment with
immunofluorescence analysis of cancer stem cell markers aldehyde dehydrogenase
1-A1 (ALDH1A1) and CD44 [234]. The treatment with PAMD-CHOL nanoparticles did
not increase the ALDH1A1+ and CD44+ cell populations in the tumors. In fact, we have
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observed statistically significant decreases in the PAMD-CHOL nanoparticle treated
groups compared to the PBS treated group (Figure 3.8H, I). This result indicates that
the treatment with the triple combination nanotherapy did not increase cancer
stemness in the tumors.
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Figure 3.8. PDAC tumor microenvironment modulation by IP-injected PAMD-CHOL
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nanoparticles. (A) Immunofluorescence analysis of α-SMA+ cells in tumors after
treatment. (B) Masson’s trichrome staining analysis in tumors after treatment. (C-I)
Immunofluorescence analysis of CD31+ blood vessels (C), CD8+ T cells (D), CD206+
M2 TAMs (E), IFN-γ cytokine (F), TNF-α cytokine (G), ALDH1A1+ cancer stem cells (H)
and CD44+ cancer stem cells (I) in tumors after treatment. Positive areas are shown
as green or magenta. Nuclei are shown as blue (DAPI). Scale bar = 100 µm. Twelve
to fifteen visual fields were randomly captured from 3 tumor sections in 5 mice per
each group for quantification. Positive area (percentage) in each field was quantified
by ImageJ software. Data are shown as mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001.

3.3.7. Inhibition of metastasis by IP administration of the PAMD-CHOL
nanoparticles
After establishing promising efficacy of the PAMD-CHOL nanoparticles on the
inhibition of the primary tumor growth and modulation of the TME, we set to investigate
the anti-metastatic activity of the particles. The used PDAC tumor model is highly
metastatic as evidenced by local invasion and widespread metastases found in the
untreated (group G1) animals. We observed macroscopic metastases in the liver,
spleen, kidney, intestine, stomach, abdominal wall, and diaphragm. Treatment with
control PAMD-CHOL/(anti-miR-NC+siNC) nanoparticles showed clear anti-metastatic
activity, indicated by the reduced metastatic frequencies in the broad range of
examined tissues when compared with the G1 group (Figure 3.9A, C). This antimetastasis activity was most likely due to the CXCR4 inhibition by PAMD-CHOL. The
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delivery of anti-miR-210 and siKRASG12D further improved the anti-metastatic activity
of the PAMD-CHOL nanoparticles, with PAMD-CHOL/(anti-miR-210+siKRASG12D)
completely inhibiting the metastasis to all observed tissues except pancreas-adjacent
splenic invasion (Figure 3.9A, C). Nanoparticle treatment started at a late tumor stage
(2 weeks) when the local splenic invasion occurred. This led to the failure of
nanoparticles to inhibit splenic invasion. Importantly, the PAMD-CHOL/(anti-miR210+siKRASG12D) nanoparticles completely inhibited liver metastasis, which is the
major metastatic site in PDAC patients (Fig. 3.9B). H&E staining showed decrease in
the metastasis area in tissues of animals treated with the PAMD-CHOL nanoparticles
(Figure 3.9D). These results confirmed the combined anti-metastatic activity of PAMDCHOL/(anti-miR-210+siKRASG12D) nanoparticles through inhibition of CXCR4 and
silencing of miR-210 and KRASG12D.
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Figure 3.9. Inhibition of metastasis by IP administration of PAMD-CHOL nanoparticles
in orthotopic PDAC mice. (A) Heat map of tumor metastasis frequency in tissues and
organs. (B) Macroscopic metastatic nodules in the liver after treatment. Data are
shown as mean ± SD (n = 5). (C) Observation of metastasis in tissues/organs after
treatment with nanoparticles (day 28). Arrows indicate metastatic tumor nodules. (D)
H&E analysis of metastasis in tissues/organs. *P < 0.05, **P < 0.01.

3.3.8. Improved survival by IP administration of the PAMD-CHOL nanoparticles
PAMD-CHOL/(anti-miR-210+siKRASG12D) nanoparticles inhibited primary tumor
growth, modulated stromal microenvironment, and inhibited widespread metastasis.
We thus studied the effect of nanoparticle treatment on survival in the orthotopic PDAC
model. In comparison with the PBS group, even the CXCR4 inhibition alone with the
PAMD-CHOL/(anti-miR-NC+siNC) treatment significantly increased median survival
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by

19%.

PAMD-CHOL/(anti-miR-210+siNC)

and

PAMD-CHOL/(anti-miR-

NC+siKRASG12D) further prolonged the survival of mice by 31% and 34%, respectively.
PAMD-CHOL/(siKRAS+miR-210) nanoparticles achieved a cooperative activity to
improve survival by 50% (Figure 3.10).

Figure 3.10. Improvement of survival by IP administration of PAMD-CHOL
nanoparticles in orthotopic PDAC mice. Kaplan–Meier survival graph of orthotopic
pancreatic tumor-bearing mice after treatment. Arrows indicate injections of
nanoparticles. 9 mice per group. Log-rank Mantel-Cox test, *P < 0.05, **P < 0.01, ***P
< 0.001.

3.3.9. Toxicity evaluation of the PAMD-CHOL nanoparticles
Toxicity evaluation of the IP-injected nanoparticles was performed. No obvious
tissue damage was found in comparison with the PBS group according to H&E staining
of major organs (Figure 3.11). Blood was collected from mice on day 28, which was
two days after the last nanoparticle injection for whole blood analysis and blood
biochemistry. PAMD-CHOL/(anti-miR-NC+siKRASG12D) nanoparticles treatment did
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not alter white blood cell (WBC), lymphocyte, monocyte, neutrophil and red blood cell
(RBC) count when compared with the PBS group, which suggested no adverse
hematologic effects, such as hemolytic anemia were caused by the nanoparticles
(Table 3.1). Liver enzymes and renal indicators were also measured. The
concentrations of AST, ALT, BUN and creatinine were within the normal range (Table
3.2). These results confirmed the overall safety of IP injected nanoparticles.

Figure 3.11. H&E staining of major organs from the orthotopic PDAC mice from
different groups to assess treatment toxicity. Scale bar = 100 µm.

91

Table 3.1. Whole blood analysis of orthotopic PDAC mice from G1 and G5 at day 28.
Data are shown as mean ± SD (n = 3).
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Table 3.2. Kidney and liver function analysis of orthotopic PDAC mice from G1 and G5
at day 28. Data are shown as mean ± SD (n = 3). *P < 0.05.

3.4. Conclusion
PDAC is an aggressive malignancy with an intense desmoplastic reaction. In this
study,

we

developed

a

triple

combination

system,

PAMD-CHOL/(anti-miR-

210+siKRASG12D), which targets the main components of the tumors with three
relevant therapeutic targets. Silencing miR-210 and KRASG12D by the PAMD-CHOL
nanoparticles led to combined anticancer activity in PDAC cells through inducing
apoptosis and inhibiting tumorigenesis. The nanoparticles also effectively inactivated
human PSCs in vitro through miR-210 inhibition. IP delivery of anti-miR-210 and
siKRASG12D by the PAMD-CHOL nanoparticles effectively silenced both miR-210 and
KRASG12D in the tumors, which resulted in combined activity to inhibit primary tumor
growth. Together with the inhibition of CXCR4/CXCL12 axis activation from PAMDCHOL polymer, the triple combination nanoparticles were capable of reverse the
tumor-suppressive microenvironment by decreasing tumor desmoplasia, tumor
microvasculature, M2 TAMs and cancer stem cells, as well as increasing cytotoxic T
cell infiltration. Silencing of both miR-210 and KRASG12D by PAMD-CHOL nanoparticles
further inhibited metastasis and prolonged survival in the orthotopic PDAC mice

93

without any obvious toxicity. In summary, triple-targeting of cancer cells, stroma, and
their interactions by IP administration of the nanotherapy represents a safe and
effective approach for combination PDAC therapy.
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Chapter 4. Exploration of preferential tumor accumulation of nanoparticles in
PDAC by IP administration
4.1. Introduction
Locoregional IP drug delivery for peritoneal tumors provides benefits due to
higher local drug concentration, longer retention time at the tumor sites, and reduced
systemic toxicity [197, 235]. Especially for PDAC, the treatment failure is largely due
to the inability of drug to reach the tumor by IV administration because of the immature
compressed tumor blood vessels and nearly impermeable dense stroma. Several
studies demonstrate the significantly improved drug accumulation in tumors by IP
injection compared to IV injection for peritoneal tumors [180, 236-238]. Encouraging
therapeutic outcomes were also reported in clinical studies using IP chemotherapy with
or without concurrent systemic therapy for the treatment of ovarian and gastrointestinal
cancers [239-241]. However, IP therapy of conventional drugs suffers from rapid drug
absorption into the systemic circulation, lack of targeting specificity for the IP tumors,
and poor drug penetration in the tumors [238, 242]. Specific drug delivery systems
such as nanoparticles represent a strategy to overcome these challenges by improving
the pharmacokinetics, tumor targeting and penetration abilities after IP administration.
The use of siRNA allows specific intervention and targeted delivery with
advantages over traditional small molecule chemotherapeutics [243]. Nanoparticles
delivering therapeutic siRNA encapsulated by functional vectors are commonly used
for the treatment of a variety of diseases. The physiochemical properties of the
nanoparticles, including size, charge and other surface properties affect the
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pharmacokinetics and tumor accumulation after IP administration. There have been
studies on the biodistribution of the nanoparticles with different properties following IP
administration, but most were performed in healthy animals [244-247].
Polo-like kinase 1 (PLK1) is a master mitotic regulator that functions in cell cycle
and stress signaling pathways. Overexpression of PLK1 is found in multiple cancer
types and is associated with poor clinical outcomes [248, 249]. The overexpression of
PLK1 contributes to oncogenesis, cancer cell proliferation, as well as the resistance to
several chemotherapies, such as gemcitabine, doxorubicin, and paclitaxel [250, 251].
Evidence shows that cancer cells with p53 or KRAS mutations are more sensitive to
the inhibition of PLK1, which leads to increased cancer cell apoptosis [252]. As
gemcitabine resistance is commonly developed in PDAC patients and p53 and KRAS
mutations are common genetic alterations [23], PLK1 is another attractive target for
PDAC therapy that was explored in our studies.
After confirming the superior nanoparticle delivery activity by IP administration in
Chapters 2 and 3, the goal of the present study was to determine the effect of
physicochemical properties of the nanoparticles on PDAC tumor delivery after IP
administration. To achieve the goal, we developed several dual-functionl nanoparticles
with

different

physiochemical

properties

capable

of

delivering siRNA and

simultaneously blocking CXCR4/CXCL12 signaling. The in vitro efficacy of the
nanoparticles delivering siRNA targeting PLK1 (siPLK1) were tested in the murine
pancreatic cancer cell line KPC8060. Preferential tumor accumulation properties of the
nanoparticles by IP administration were evaluated in orthotopic pancreatic tumor
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bearing mice. The in vivo anti-tumor and anti-metastasis efficacy was studied with the
best-performing nanoparticles delivering siPLK1 to take advantage of the combined
effect of PLK1 downregulation and CXCR4 antagonism.
4.2. Materials and methods
4.2.1. Materials
AMD3100 was purchased from Biochempartner (Shanghai, China). HMBA was
from Pfaltz&Bauer (Waterbury, CT). mPEG-Acrylamide (2 kDa) purchased from
Creative PEGworks (Winston-Salem, NC). Cholesteryl chloroformate, 2,3,5,6Tetrafluoro-p-toluic
trifluorotoluene

acid

were

(TFTA),

obtained

4-(Dimethylamino)
from

Sigma-Aldrich

pyridine
(St.

(DMAP)

Louis,

MO).

and
N-

hydroxysuccinimide (NHS), N, N’-dcyclohexylcarbodiimide (DCC) and DIPEA was
from Acros Organics (Fair Lawn, NJ). Cyanine3 NHS ester was purchased from
Lumiprobe (Hunt Valley, MD). PBS, DMEM, FBS, trypsin and Pen-Strep solutions were
obtained from Thermo Scientific (Waltham, MA). SiRNA targeting PLK1 (siPLK1,
sequence: 5’-CAACACGCCUGAUUCUCUA-3’), scramble siRNA nonspecific to any
mouse gene (siScr, sequence: 5’-AUGAACGUGAAUUGCUCAA-3’), GE Healthcare
Dharmacon (Lafayette, CO). TRIzol® reagent was purchased from Life Technologies
(Carlsbad, CA).
4.2.2. Methods
4.2.2.1. Polymer synthesis and characterization
PAMD-PEG [253] and PAMD-CHOL [194] were synthesized and characterized as
previously described. Briefly, the parent PAMD polymer was synthesized by Michael
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addition of 1:1 mole ratio of AMD3100 and HMBA. After three days of reaction at 37 °C
in oxygen free condition, the reaction mixture was dialyzed against methanol to remove
unreacted small molecules. The polymer structure was confirmed by 1H-NMR using
Varian INOVA (500 MHz) and the polymer molecular weight was measured by GPC
using Agilent 1260 Infinity LC system equipped with a miniDAWN TREOS multiangle
light scattering detector and an Optilab T-rEX refractive index detector from Wyatt
Technology (Santa Barbara, California). TSKgel G3000PWXL-CP Column (Tosoh
Bioscience LLC, King of Prussia, Pennsylvania) was used with 0.1 M sodium acetate
buffer (pH 5.0) as the mobile phase at a flow rate of 0.5 mL/min. Results were analyzed
using Astra 6.1 software. Poly(ethylene glycol) was conjugated to the PAMD polymer
by Michael addition of the double bond in mPEG-Acrylamide (2 kDa, 100 mg) with the
secondary amines of AMD3100 in the PAMD (200 mg) at 50 °C for two days.
Cholesterol was conjugated by carbamoylation of the chloroformate group in
cholesteryl chloroformate (43.2 mg) with the secondary amines in PAMD (200 mg) in
anhydrous dichloromethane with DIPEA (62.2 mg) for overnight. The conjugation of
TFTA to the PAMD was through DCC/NHS coupling [254]. TFTA (114.5 mg) was
activated by DCC (227.0 mg) and HNS (126.6 mg) for 3 h in DMF and DMAP (134.4
mg) and PAMD polymer (200 mg) were added to the reaction afterwards and stirred
for another 5 days at room temperature. All the polymers were purified by dialysis
(7000 MWCO) in methanol for 1 day, followed by dialysis in deionized water with pH
adjusted to 3-4 by 10% HCl solution and further in pure deionized water for another
day. The final polymer products were obtained by lyophilization as hydrochloride salts
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and named as PAMD-PEG, PAMD-CHOL and PAMD-TFTA. The conjugation ratio of
PEG and cholesterol to the polymer were determined by 1H-NMR as 53.7% (w/w) and
16.6% (w/w) respectively. The conjugation ratio of 2,3,5,6-Tetrafluoro-p-toluic acid was
determined by

F-NMR with internal standard trifluorotoluene as 18.4% (w/w).
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Cyanine3 NHS ester was conjugated to the polymers to obtain Cyanine3 labeled
polymers (Cy3-PADM-PEG, Cy3-PAMD-CHOL, Cy3-PAMD-TFTA) following the
manufacturer’s protocol.
4.2.2.2. Cell culture
Pancreatic cancer cell line KPC8060 derived from PDAC mouse model (KrasLSL‑
G12D/+

; Trp53LSL‑R172H/+; Pdx-1-Cre) was kindly provided by Dr. Hollingsworth at UNMC.

The cells were cultured in high-glucose DMEM with 10% FBS and Pen-Strep (100
U/mL, 100 μg/mL). Human epithelial osteosarcoma U2OS cells (Fisher Scientific) with
functional EGFP-CXCR4 fusion protein expressing were cultured in DMEM with 10%
FBS, 2 mM L-glutamine, 0.5 mg/mL G418 Sulfate and Pen-Strep (100 U/mL, 100
μg/mL). All cells were cultured at 37 °C with 5% CO2 in a humidified incubator.
4.2.2.3. CXCR4 antagonism assay
CXCR4 redistribution assay was used to determine the effectiveness of the
CXCR4 antagonism of the polymers. U2OS cells were seeded in black 96-well plate
24 h before treatment. Cells were treated with various concentrations of polymers or
polyplexes for 30 min and SDF1 was added and incubated for 1 h afterwards. Cells
were fixed with 4% paraformaldehyde solution and nuclei were stained with Hoechst33258. Cellomics ArrayScan VTI High Content Analysis Reader (Thermo Scientific)
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and SpotDetectorV3 BioApplication software were used to analyze the internalized of
the EGFP-CXCR4 receptors. The relative CXCR4 antagonism was calculated with
AMD3100 (300 nM) set as 100% antagonism and SDF1 only group as 0%. EC50 was
obtained from the dose-response curve in GraphPad software. Images were taken by
EVOS fl microscope at 20 ×.
4.2.2.4. Cytotoxicity of the polymers in vitro
Cytotoxicity of the polymers were evaluated in KPC8060 cells by CellTiter-Blue
Cell Viability Assay. KPC8060 cells were seeded in 96-well plates at the density of
4000 cells per well 24 h before polymer treatment. The original medium was replaced
with serial dilutions of the polymers PEI (10k), PAMD-PEG, PAMD-CHOL and mPAMDTFTA in cell culture medium and incubated for another 24 h. The mixture of 100 μl cell
culture medium and 20 μl CellTiter-Blue reagent were added into each well after
removal of the media with polymers. After 2 h incubation, the fluorescence intensity [FI]
was measured at λex/λem= 560/590 nm by Microplate Reader (Molecular Devices, CA).
The relative cell viability (%) was calculated as [FI]treated/[FI]untreated × 100. Polymer
concentration that caused 50% decrease in cell viability were defined as IC50 and autocalculated in GraphPad Prism with the dose-response analysis.
4.2.2.5. Transwell migration assay
KPC8060 cells were trypsinized, washed and resuspended in serum free DMEM
medium. Cells were pretreated with polymers for 20 min and 4 × 104 cells in 300 μl
medium were added into each insert (8.0 μm pores, Fisher Scientific, Pittston, PA).
600 μl DMEM medium with or without (negative control) 10% FBS were added into the
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24-well plates in contact with the bottom of the cell containing insert. 16 h after
incubation, unmigrated cells at the top of the chamber were removed by cotton swabs
and migrated cells at the bottom of the chamber were fixed and stained with 0.2%
Crystal Violet. The migrated cells were counted at 20 × magnification using EVOS xl
microscope.
4.2.2.6. Nanoparticle formulation design and characterization
Polymer/siRNA nanoparticles were prepared by thoroughly mixing equal volume
of solutions containing polymer and siRNA diluted in HBG buffer (20 mM HEPES, pH
7.4), followed by 20 min incubation at room temperature for the nanoparticle to selfassemble. Further mixture of the resultant polymer/siRNA nanoparticles with same
volume of human serum albumin (HSA) solution and incubation for 20 min gave the
HSA coated nanoparticles (polymer/siRNA/HSA). The ability of the polymers to
condense siRNA was tested by agarose gel electrophoresis assay. Polymer/siRNA
nanoparticles were prepared at different w/w ratios and loaded into the wells in 2%
agarose gel containing 0.5 μg/mL ethidium bromide. The gel was run at 75 V in 0.5 ×
Tris/Borate/EDTA buffer for 30 min and imaged under UV with KODAK Gel Logic 100
imaging system. HSA coated nanoparticles also underwent electrophoresis to make
sure HSA coating would not result in the release of the siRNA. Hydrodynamic size and
zeta-potential of the nanoparticles were measured by dynamic light scattering using a
ZEN3600 Zetasizer Nano-ZS Malvern Instruments Ltd., MA).
4.2.2.7. Cellular uptake of the nanoparticles in vitro
Cellular uptake of the siRNA by different nanoparticles were visualized by confocal
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microscopy and quantified by flow cytometry.
Cellular uptake in cell monolayers: KPC8060 cells were seeded in the 8-well glass
chamber (Catalog #: 155409, Fisher Scientific). 24 h after seeding, the medium was
removed and nanoparticles containing Cy5-labeled siRNA (Cy5-siRNA) was diluted in
serum free medium and added into each well. After 4 h incubation, cells were washed
and stained with Hoechst 33342 for live cell imaging. Uptake of the Cy5-siRNA in each
formulation was visualized and imaged by confocal microscopy (LSM800 Laser
Scanning Microscope, Zeiss, Jena, Germany). For quantitative measurement, cells
were seeded in 12-well plate and treated accordingly. After 4 h, cells were trypsinized
and washed twice for flow cytometry analysis.
Cellular uptake in multicellular tumor spheroids: KPC8060 spheroids were made
by seeding 1 × 104 cells in 2% agarose coated 48-well plates and cultured for 7 days
for them to reach the diameter of around 400 μm. nanoparticles containing Cy5-siRNA
were diluted in serum free medium and incubated with the spheroids for 12 h. After
that, spheroids were washed with PBS twice and observed under the confocal
microscope. Z-stack images of the spheroids were taken every 10 μm intervals.
Surface-plot images of the spheroids were created by Fiji software with the
transformation of the z-stack fluorescent images.
4.2.2.8. Transfection efficacy of the nanoparticles in vitro
Transfection efficacy of the nanoparticles delivering siPLK1 in KPC8060 cells or
spheroids were evaluated by quantitative real-time polymerase chain reaction of the
PLK1 mRNA level, cell killing efficacy and of inhibition of colony formation ability.
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Real-time Polymerase Chain Reaction: KPC8060 cells were seeded in 12-well
plates at the density of 1.5 × 104 cells per well. Cells were treated with different
nanoparticles delivering siPLK1 or siScr in serum free medium for 4h and then the
nanoparticles were removed and changed to culture medium. 2 days later, total RNA
was extracted with TRIzol® reagent following the protocol. The mRNA levels of PLK1
were analyzed by SYBR Green RT-PCR. Extracted RNA (0.5 μg) was converted into
cDNA using High Capacity cDNA transcription kit (Applied Biosystems). The PCR
reactions were run on the Rotor-Gene Q (QIAGEN) equipment with iTaq Universal
SYBR

Green

Supermix

(Bio-Rad)

and

GAPDH

primers

(forward:

5’-

CAATGACCCCTTCATTGACC; reverse: 5’-GATCTCGCCCTGGAAGATG) and PLK1
primers

(forward:

5’-CTCAATAAAGGTGTGGAGAAC;

reverse:

5’-

TGTAGCAAGTCACTAAGGTG). Relative mRNA levels were calculated based on the
comparative threshold value (Ct) method. PLK1 mRNA level in tumor spheroids was
also evaluated with the same procedure after treated with the nanoparticles for 48 h.
Cell killing assay: KPC8060 cells were seeded in 96-well plates at the density of
2000 cells per well. 24 h later, cells were treated with different nanoparticles in serum
free medium for 4h. After that, the medium was aspirated and replaced by culture
medium and cells were cultured for another 44 h. Cell killing efficacy of the
nanoparticles was evaluated by CellTiter-Blue Cell Viability Assay as described above.
Cell killing efficacy of the nanoparticles in tumor spheroids was assessed by the
Live/Dead Assay Explorer Kit (Molecular Devices, USA) after spheroids were treated
with different nanoparticles for 48 h. Images were obtained by EVOS fl microscope at
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10 ×.
Colony formation assay: KPC8060 cells were seeded in the 12-well plates with
300 cells per well. After 24 h, cells were treated with different nanoparticles and
cultured for another 7 days. KPC8060 cells were fixed by 4% paraformaldehyde,
stained with 0.2% Crystal Violet and washed with deionized water. Percent colony
areas to the whole well area were semiquantified by Image J software.
4.2.2.9. In vivo biodistribution
Orthotopic KPC-derived pancreatic cancer model was established by injection of
2.5 × 104 of KPC8060 cells into the tail of the pancreas (details described in Chapter
2, Methods 2.2.2.5). Tumor bearing mice were randomly assigned into 6 groups, which
are siRNA, PAMD-PEG/siRNA, PAMD-CHOL/siRNA, mPAMD-TFTA/siRNA, PAMDCHOL/siRNA/HSA

and

mPAMD-TFTA/siRNA/HSA.

Polymers

used

in

this

biodistribution study were conjugated with Cyanine3 dye (Cy3-polymer) and siRNA
was labeled with Cyanine5.5 dye (Cy5.5-siRNA). Different formulations of
nanoparticles containing 20 μg siRNA were IP injected into the tumor bearing mice 24
days after the inoculation of the KPC8060 cells. 4 h and 24 h after the injection of the
nanoparticles, mice were sacrificed. Primary tumors and major organs were collected
for ex vivo imaging using Xenogen IVIS 200 (Ex=535 nm, Em=580 nm for Cy3 and
Ex=675, Em=720 for Cy5.5). Primary tumor tissues were embedded in O.C.T
compound right after IVIS imaging and cut into frozen sections (10 μm) and imaged by
confocal microscopy.
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4.2.2.10. In vivo therapeutic efficacy
Two weeks after the establishment of the orthotopic pancreatic tumors, the mice
were randomly assigned into three groups (n=6) and administered with PBS or
mPAMD-TFTA/siScr or mPAMD-TFTA/siPLK1(1.2 mg/kg siRNA, 6 mg/kg mPAMDTFTA polymer) every other day by IP injection for a total of 7 doses. Mice body weight
were recorded every other day during the whole study. Tumor sizes were monitored by
ultrasound on day 12, 19, 27 post tumor inoculation. All the mice were sacrificed on
day 28. Primary tumors were weighed and metastasis in each organ was recorded for
each mouse. Primary tumors were fixed in 10% neutral buffered formalin and sectioned
for immunohistochemical analysis.
4.2.2.11. Histochemical analysis
Tumors and major organs were fixed in 10% neutral buffered formalin and then
stored in 75% ethanol. The tissues were embedded in paraffin, sectioned, and stained
with H&E. Images were taken by EVOS fl microscope.
4.2.2.12. Statistical analysis
All statistical analysis was performed with GraphPad Prism v5. Data are presented
as mean ± SD. Unpaired Student’s t test was used to analyze the statistical significance
between two groups while One-way ANOVA was used to analyze statistical differences
among three or more groups. P < 0.05 was considered as a minimal level of statistically
significance.
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4.3. Results and discussion
4.3.1. Synthesis and characterization of CXCR4-inhibiting polymers
Synthetic polymers have been extensively developed as gene delivery vectors
with various different purposes [255, 256]. Our lab has developed the polymeric
AMD3100 (PAMD, Figure 4.1A) with repeating unit of AMD3100, an FDA approved
small molecule, as the effective and specific CXCR4 antagonist [178]. The cationic
character from the protonated secondary amines of AMD3100 confers the polymer the
ability to condense negatively charged nucleic acids. Although PAMD has been
reported as effective DNA delivery vector [257], its siRNA delivery activity is limited.
Chemical modifications can give different properties to the polymers and the resultant
nanoparticles. Here, we describe the modification of PAMD with polyethylene glycol
(PEG), cholesterol and 2,3,5,6-tetrafluoro-p-toluic acid (TFTA).
The modification of PAMD with PEG or cholesterol were previously reported by
our lab [194, 253]. To improve the safety of the polymer and colloidal stability of the
nanoparticle, PEG was conjugated to PAMD by Michael addition of mPEG-acrylamide
with secondary amines of the AMD3100 moieties to result in PAMD-PEG (Figure 4.1B).
Cholesterol is a naturally occurring hydrophobic lipid that is readily metabolized in the
body. Modification of the polymers with cholesterol enhanced stability and cellular
uptake attributed to favorable interactions between cholesterol moiety and cell
membrane [193, 258]. Here, PAMD was modified with cholesterol by nucleophilic
substitution reaction of cholesterol chloroformate and secondary amine groups of
PAMD to yield PAMD-CHOL (The same batch of PAMD-CHOL was used throughout
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the whole dissertation) (Figure 4.1C). Fluorocarbons are both hydrophobic and
lipophobic and exhibit a high phase separation tendency in biological environments
[259-261]. Fluorination of the polycations is a recent strategy for improving stability and
transfection efficacy. Thus, we introduced TFTA as the fluorinated moiety to PAMD.
The carboxyl group of TFTA was first activated by DCC and NHS and then PAMD and
DMAP were added dropwise for conjugation to give the final product of PAMD-TFTA
(Figure 4.1D).
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Figure 4.1. Synthesis and modification of anti-CXCR4 Polymers. (A) Synthesis of antiCXCR4 polymers PAMD. (B-D) Modification of PAMD with polyethylene glycol (PAMDPEG) (B), cholesterol (PAMD-CHOL) (C) and 2,3,5,6-tetrafluoro-p-toluic acid (PAMDTFTA) (D).

The molecular weight of the parent PAMD was measured by GPC and the
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molecular weights of the modified PAMD polymers were calculated from the
corresponding modification content determined by NMR (Table 4.1). The contents of
the PEG and cholesterol in the polymers were determined from 1H-NMR integration
(Figure 4.2A, B) as described before [194, 253]. Successful conjugation of TFTA to the
polymer was verified by 19F-NMR (Figure 4.2C, D). The fluorine peaks of the polymer
slightly shifted compared to the small molecule TFTA and the sharp multiplet fluorine
peaks from TFTA became two broad single peaks resulting from the conjugation to the
polymer. The content of TFTA moieties was also determined by

F-NMR with the

19

addition of a known concentration of the internal standard trifluorotoluene.

Table 4.1. Polymer characterization. Mol % represents the mol ratio of the conjugated
chemicals (PEG, CHOL, or TFTA) to one repeating unit of PAMD. Wt. % represents
the weight ratio of the conjugated chemicals to the whole polymer.

Mw= weight-average molecular weight. a From GPC. b From 1H-NMR. c From 19F-NMR.
d

Calculated from the Mw of the PAMD and corresponding modified chemical content.
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(D) with internal standard trifluorotuene in methanol-d4.
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4.3.2. CXCR4 antagonism and anti-migration activity of the polymers
CXCR4 antagonism of the polymers was tested by CXCR4 redistribution assay in
engineered U2OS cells. The cells express EGFP-labeled CXCR4 receptors on the
plasma membrane, which are internalized into the cells after binding of CXCL12.
AMD3100 at the concentration of 300 nM was used as a positive control and set as
100% CXCR4 antagonism. The PAMD, PAMD-PEG and PAMD-CHOL showed dosedependent CXCR4 antagonistic activity with EC50 at 0.048, 0.11 and 0.12 μg/mL
respectively (Figure 4.3A). In contrast, PAMD-TFTA showed poor anti-CXCR4 effect
(Figure 4.3B), which could be explained by the higher conjugation ratio of TFTA to
PAMD (85.6 mol %) when compared to PAMD-PEG (41.0 mol %) and PAMD-CHOL
(34.9 mol %). The modification compromised the anti-CXCR4 activity of the cyclam by
shielding the receptor-binding site. We thus used a mixture of the parent PAMD and
PAMD-TFTA. Different w/w ratios of PAMD and PAMD-TFTA were tested for antiCXCR4 effects at mixed polymer concentrations of 0.5, 1.5 and 3 μg/mL. A mixture
consisting of as little as 20% PAMD showed 100% CXCR4 antagonism at total mixed
polymer concentration of 0.5 μg/mL (Figure 4.3C). Thus, this polymer mixture (denoted
as mPAMD-TFTA) was used for all the following studies. Dose-response analysis of
mPAMD-TFTA showed CXCR4 antagonism with EC50 at 0.81 μg/mL (Figure 4.3A). All
the polymers showed 100% CXCR4 antagonism at 2 μg/mL concentration as shown
by the retention of the EGFP-CXCR4 at the cell surface (Figure 4.3D).
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Figure 4.3. CXCR4 antagonism of the polymers by CXCR4 redistribution assay. (A)
CXCR4 antagonism of AMD3100 monomer and the polymers in U2OS cells by CXCR4
redistribution assay (mPAMD-TFTA represents the mixture of 80% (w/w) PAMD-TFTA
and 20% (w/w) PAMD polymers). (B) CXCR4 antagonism of AMD3100 monomer and
PAMD-TFTA polymer. (C) CXCR4 antagonism of PAMD-TFTA and PAMD polymer
mixtures. (D) Representative images of EGFP-CXCR4 distribution in U2OS cells
treated with different drugs. The concentration of AMD3100 was 300 nM and all the
polymers were 2 μg/ml. Scale bar= 200 μm.

Blocking of CXCR4/CXCL12 signaling inhibits migration of cancer cells [262-264].
Here, we tested the anti-migration effect of the polymers in murine pancreatic cancer
cells KPC8060 (Figure 4.4). The cells were pretreated with the polymers (2 μg/mL) or
AMD3100 (300 nM) for 30 min and then migration was induced by 10% FBS. With FBS
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as the chemoattractant, blockage of CXCR4 solely with AMD3100 was not sufficient
for the suppression of KPC8060 cell migration. However, treatments with PAMD-PEG,
PAMD-CHOL and mPAMD-TFTA significantly inhibited the migration, suggesting the
polymerization of AMD3100 may achieve additional benefits that was able to block
other signaling pathways related with the components of FBS to impede the migration.

Figure 4.4. Anti-migration effect of AMD3100 and the polymers in KPC8060 cells
induced by 10% FBS. Five areas of each insert were randomly captured under 20x
view of the microscope and the number of migrated KPC8060 cells were counted. Data
are expressed as mean±SD (n=3). ***P < 0.001.

4.3.3. Preparation and characterization of the siRNA nanoparticles
The ability of the polymers to condense siRNA and form nanoparticles was
evaluated by agarose gel retardation assay (Figure 4.5A). PAMD-CHOL had the best
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siRNA condensation ability as it fully condensed siRNA at the polymer to siRNA w/w
ratio ≥ 1. Meanwhile, mPAMD-TFTA and PAMD-PEG were able to achieve the same
effect at w/w ≥ 2.5 and 5 respectively. The relatively low siRNA condensation ability of
mPAMD-TFTA and PAMD-PEG compared to PAMD-CHOL in terms of polymer to
siRNA w/w could be explained by higher molar ratio of TFTA shielding the positive
charges of the polymer and the higher weight content of the PEG moiety.
The nanoparticles were prepared by mixing equal volume of polymer and siRNA
solutions at predetermined w/w ratios and incubating at room temperature for 20 min
before use. The hydrodynamic size and zeta-potential of the nanoparticles were
measured by DLS. Tested formulations included PAMD-PEG/siRNA (w/w 5), PAMDCHOL/siRNA (w/w 2.5), and mPAMD-TFTA/siRNA (w/w 5). All the prepared
nanoparticles were narrowly distributed with sizes ranging from 80 to 140 nm (Figure
4.5B). PAMD-PEG/siRNA nanoparticles had nearly neutral zeta potential, while PAMDCHOL/siRNA and mPAMD-TFTA/siRNA nanoparticles were positively charged (~20
mV).
For the purpose of testing nanoparticles with diverse physiochemical properties,
negatively charged nanoparticles were prepared by coating the positively charged
PAMD-CHOL/siRNA and mPAMD-TFTA/siRNA nanoparticles with negatively charged
HSA. Albumin is the most abundant protein in the blood and ascites and is involved in
many important biological processes [265, 266]. Albumin-based drug formulations
have been reported to have less toxicity, better stability and improved
pharmacokinetics [267-269]. The ternary nanoparticles were prepared by mixing of

113

HSA with the positively charged nanoparticles. The introduction of the HSA did not lead
to the release of the siRNA from the nanoparticles as confirmed by gel electrophoresis
(Figure

4.5C).

PAMD-CHOL/siRNA/HSA

at

w/w

2.5/1/25

and

mPAMD-

TFTA/siRNA/HSA at w/w 5/1/50 formulations showed hydrodynamic sizes around 130
nm with zeta-potential of -10 mV.

Figure 4.5. Preparation and characterization of the nanoparticles. (A) siRNA
condensation ability of PAMD-PEG, PAMD-CHOL and PAMD-TFTA polymers
evaluated by gel electrophoresis assay. (B) Hydrodynamic size and zeta-potential of
the nanoparticles with different formulations. (C) Influence of HSA addition in siRNA
release from polymer/siRNA nanoparticles by electrophoresis assay.
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4.3.4. Cellular uptake of the nanoparticles in PDAC cell monolayers and
multicellular spheroids
After the preparation of the nanoparticles, their siRNA delivery effect was
examined in KPC8060 cells. The toxicity of the polymers was tested first to ensure safe
doses were used for the following studies (Figure 4.6). The modification of PEG greatly
improved the safety of the polymer with IC50 of 249 μg/mL in KPC8060 cells. PAMDCHOL (IC50=17.6 μg/mL) showed increased cytotoxicity compared to mPAMD-TFTA
(IC50=27.9 μg/mL) probably due to the higher density of the positive charges. All the
modified

PAMD

polymers

exhibited

less

cytotoxicity

compared

to

control

polyethylenimine (PEI) (IC50=8.0 μg/mL). Due to polymer toxicity, we used safe
polymer concentrations that can ensure at least 90% cell viability. In that case,
mPAMD-TFTA/siRNA and mPAMD-TFTA/siRNA/HSA nanoparticles were used at 50
nM siRNA, while other groups were used with up to 100 nM siRNA for the treatment of
PDAC cell monolayers.

Figure 4.6. Cytotoxicity of the polymers in KPC8060 cells. Cytotoxicity (A) and IC50 (B)
of PEI, PAMD-PEG, PAMD-CHOL and mPAMD-TFTA polymers in KPC8060 cells.
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The KPC8060 cells were incubated with the nanoparticles prepared with Cy5labeled siRNA (Cy5-siRNA) for 4 h and observed by confocal microscope (Figure 4.7A).
Like the untreated and siRNA only groups, almost no siRNA signal (green) was
observed in the PAMD-PEG/siRNA treated group. This result is within our expectation
as PEG modification leads to reduced cellular uptake and lowered transfection efficacy
due to diminished surface interactions with cell membranes [253, 270, 271]. Other
nanoparticle treated groups all showed significant siRNA uptake by KPC8060 cells.
Surprisingly, mPAMD-TFTA/siRNA and mPAMD-TFTA/siRNA/HSA nanoparticles
showed the highest cellular uptake even at half siRNA concentration. The addition of
HSA did not seem to influence the uptake of siRNA in cells. Quantification of the siRNA
uptake by fluorescent intensity was done by flow cytometry (Figure 4.7B). In
accordance with the confocal microscopy observations, mPAMD-TFTA/siRNA and
mPAMD-TFTA/siRNA/HSA had the highest cell uptake as shown from the mean
fluorescent intensity, which was ~2.6 times higher than PAMD-CHOL/siRNA and
PAMD-CHOL/siRNA/HSA, and ~40 times higher than PAMD-PEG/siRNA group.
Nearly all KPC8060 cells internalized the siRNA delivered by modified PAMD polymers
regardless of the surface charge, while the naked siRNA had only 50% cellular uptake
with minimal fluorescent signals detected.
Cellular uptake in cell monolayers may not be representative of the situation in
actual tumors. To better mimic the tumor, the uptake and penetration ability of the
nanoparticles were evaluated in KPC8060 multicellular 3D spheroids (Figure 4.7C).
The spheroids were prepared by plating 10,000 cells into the ultra-low attachment 96-
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well plates per well and cultured for 7 days when the spheroids diameter reached ~400
μm. Higher concentrations of siRNA were used in this study with mPAMD-TFTA/siRNA
and mPAMD-TFTA/siRNA/HSA nanoparticles encapsulating 100 nM siRNA and other
groups encapsulating 200 nM siRNA. The spheroids were incubated with
nanoparticles containing Cy5-siRNA for 12 h and observed by confocal microscope. Zstack images of the spheroids were taken and transformed to 3D surface plot images
by Fiji software shown in Figure 4C. Positively charged nanoparticles exhibited
significant uptake and spheroid penetration, with mPAMD-TFTA/siRNA nanoparticles
performing the best, followed by PAMD-CHOL/siRNA nanoparticles. However, HSAcoated nanoparticles showed weakened penetration ability. This may probably be
attributed to the higher affinity of positively charged nanoparticles to the negatively
charged cell membrane. Wang et al. [272] also demonstrated the superior penetration
capability of the cationic nanoparticles both in multicellular spheroids and in tumors
after IV injection compared to the neutral and anionic counterparts. PAMD-PEG/siRNA
and siRNA only treatment groups failed to show abilities for penetration.
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Figure 4.7. Cellular uptake of the nanoparticles in KPC8060 cell monolayers and
multicellular spheroids. (A) Confocal microscopy observation of KPC8060 cells with
different treatments containing Cy5-siRNA for 4 h. Cy5-siRNA was shown in green and
nuclei were shown in blue (DAPI). Scale bar = 20 μm. (B) Flow cytometry analysis of
the Cy5-siRNA uptake by KPC8060 cells with different treatments for 4 h. (C) 3D
surface plots of tumor spheroids with different treatments containing Cy5-siRNA for 12
h. Treatments of monolayered cells used 50 nM siRNA for PAMD-TFTA/siRNA and
PAMD-TFTA/siRNA/HSA groups and 100 nM siRNA for other groups. Treatments of
multicellular spheroids used 100 nM siRNA for PAMD-TFTA/siRNA and PAMDTFTA/siRNA/HSA groups and 200 nM siRNA for other groups.

118

4.3.5. Transfection efficacy of the nanoparticles in PDAC cell monolayers and
multicellular spheroids
We then studied the transfection efficacy of the nanoparticles in KPC8060 cells by
evaluating the relative mRNA levels, cell killing and inhibition of colony formation
activity. We used PLK1 as the target gene in this study to evaluate anti-cancer activity
by the nanoparticles delivering siPLK1 in KPC8060 cells. PLK1 gene knockdown by
siPLK1 could lead to cancer cell apoptosis by inducing cell cycle arrest [273, 274].
Nanoparticles encapsulating scrambled siRNA were used as a control. KPC8060 cells
were treated with different nanoparticles delivering siPLK1 or siScr for 48 h. Relative
PLK1 mRNA levels after treatment were evaluated by RT-PCR (Figure 4.8A). mPAMDTFTA/siPLK1(50 nM) and mPAMD-TFTA/siPLK1(50 nM)/HSA treatments had the best
knockdown effect as PLK1 level in the two groups was downregulated by ~65%.
PAMD-CHOL/siPLK1 and PAMD-CHOL/siPLK1/HSA groups also showed significant
downregulation of PLK1 expression by 35% and 49%, respectively, but required 100
nM siRNA. PAMD-PEG/siPLK1 nanoparticles did not show any PLK1 knockdown as
expected from the negligible uptake by the cancer cells. Anti-cancer activity of the
nanoparticles was studied by testing the cell viability using CellTiter-Blue Assay (Figure
4.8B) and inhibition of colony formation (Figure 4.8C, D). Treatment with mPAMDTFTA/siPLK1 and mPAMD-TFTA/siPLK1/HSA nanoparticles resulted in ~60% cell
killing, while that of PAMD-CHOL/siPLK1 and PAMD-CHOL/siPLK1/HSA nanoparticles
resulted in ~50% cell death. For the colony formation assay, mPAMD-TFTA/siPLK1
and mPAMD-TFTA/siPLK1/HSA groups greatly inhibited the colony formation and
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growth. The other two treatment groups showed a modest inhibitory effect. Overall, all
the nanoparticles delivering siPLK1, except PAMD-PEG/siPLK1, were capable of
downregulating PLK1 and exhibiting notable anti-cancer efficacy with mPAMDTFTA/siRNA nanoparticles displaying the best effect.
We then evaluated the transfection activity of the mPAMD-TFTA/siRNA
nanoparticles in KPC8060 multicellular spheroids. Relative PLK1 mRNA level in the
tumor spheroids was reduced by ~33% after treatment with mPAMD-TFTA/siPLK1
nanoparticles for 48 h (Figure 4.8E). The subsequent cell killing effect was examined
by live/dead viability assay (Figure 4.8F). The spheroids were stained with calcein AM
(live cells) and EthD-1 (dead cells) and imaged by fluorescence microscope. The
untreated and mPAMD-TFTA/siScr treated groups showed minimal number of dead
cells (shown as red) while the mPAMD-TFTA/siPLK1 treatment showed much
increased number of dead cells and decreased number of live cells (shown as green),
indicating ability to achieve strong anti-cancer effect not only in a 2D monolayer but
even in 3D environment.
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Figure 4.8. Transfection efficacies of the nanoparticles in KPC8060 cells and
multicellular spheroids. (A) Levels of PLK1 mRNA level in KPC8060 cells after
treatment of nanoparticles for 48 h. (B) Cell viability assay by CellTiterBlue Assay after
treatment of nanoparticles for 48 h. (C) Colony formation assay of after treatment of
nanoparticles for 48 h. Colony areas were quantified by ImageJ software. (D)
Representative images of the colonies in each group. (E) Levels of PLK1 mRNA level
in KPC8060 multicellular spheroids after treatments for 48 h. (F) Representative
images of live/dead viability assays in KPC8060 multicellular spheroids after
treatments for 48 h. Live cells were stained with Calcein AM (green), while dead cells
were stained with EthD-III (red). Scale bar = 400 μm. Treatments of monolayered cells
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used 50 nM siRNA for PAMD-TFTA/siRNA and PAMD-TFTA/siRNA/HSA groups and
100 nM siRNA for other groups. Treatments of multicellular spheroids used 100 nM
siRNA for PAMD-TFTA/siRNA and PAMD-TFTA/siRNA/HSA groups and 200 nM siRNA
for other groups. All the data are shown as mean ± SD (n=3). Significances are all
compared with PBS group, * P < 0.05, ** P < 0.01, *** P < 0.001.

4.3.6. Biodistribution in orthotopic PDAC model following IP administration
The in vivo fate of the nanoparticles after IP administration largely depends on
their physiochemical properties, including particle size, charge and other surface
properties [246, 275, 276]. Smaller nanoparticles were reported to distribute more
uniformly in the peritoneum and to penetrate into peritoneal tumors more efficiently
[247], however, they were also prone to rapid clearance by lymphatic system than
larger particles [276]. A balance in particle size between improved penetration and
longer retention time should be reached for optimal delivery. Dadashzadeh et al.
reported a good peritoneal retention for 100 nm positively charged liposomes when
compared with liposomes with different charges and sizes [275]. Thus, the
nanoparticles we prepared and used in this study were all ~100 nm. To understand
how physicochemical properties affect the tumor accumulation of the nanoparticles in
vivo, biodistribution study was conducted in orthotopic PDAC model using the same
cells from in vitro studies above. The PDAC model was initiated by pancreatic injection
of 2.5 × 104 of KPC8060 cells. Nanoparticles prepared with Cy5.5-labeled siRNA and
Cy3-labeled polymer were injected IP 24 days after tumor inoculation when the primary
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tumor reached about 10 mm in diameter with metastasis to other organs. The siRNA
dose used for each treatment group was 20 μg per mouse, but the amount of the
polymers was different because of different formulation weight ratios. The siRNA and
polymer fluorescence in tumors and different organs were visualized by IVIS imaging
4 and 24 h after administration and the fluorescence intensity was semi-quantified by
the IVIS software.
We first established the biodistribution profile of naked siRNA (Figure 4.9A). As
expected, the highest accumulation of the naked siRNA was observed in the kidneys
followed by the liver 4 h after the IP administration. The fluorescence further dropped
down 24 h after injection (Figure 4.9B). Only ~28% of the siRNA fluorescent intensity
was detected in primary tumors at 4 h compared to that in kidneys and decreased
tendency was also shown at 24 h. Naked siRNA has an extremely short half-life in vivo
[277, 278] and was likely degraded 24 h after injection leaving the Cy5.5 dye in the
tumors and other organs. IP treatment with neutral PAMD-PEG/siRNA nanoparticles
showed similar results to the naked siRNA (Figure 4.9A, B). This indicated the
instability and rapid siRNA release from the PAMD-PEG/siRNA nanoparticles. The
premature release of the siRNA was also reported for PEGylated liposomes when
administered IP [266], possibly due to a weak complexation of the siRNA to the polymer
or liposome in the presence of PEG. Interestingly, the PAMD-PEG polymer itself
showed significant accumulation in primary PDAC tumor. This may be attributed to the
reduced nonspecific uptake by the RES in liver and spleen following IP administration
compared to IV administration [238] and the aberrant peri-tumor mesothelium [180,
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279]. The fluorescence intensity of the PAMD-PEG polymer decreased at 24 h
compared to 4 h, suggesting a short IP retention time, which is in correspondence with
Colby et al. [279] who demonstrated PEG surface modification leading to a more rapid
nanoparticle clearance from the peritoneal cavity.
The remaining four tested nanoparticles, including positively and negatively
charged ones, showed significant accumulation of both siRNA and polymers in primary
tumors (Figure 4.9A, B). The siRNA accumulation in tumors displayed an increasing
tendency at 24 h compared to 4 h, indicating improved IP retention and controlled
absorption. For mPAMD-TFTA nanoparticles, with or without HSA, extremely low
kidney siRNA distribution was observed, suggesting that the TFTA modification
stabilized the particles and minimized premature siRNA release. The highest siRNA
uptake in primary tumors was observed in the mPAMD-TFTA/siRNA nanoparticle
treated group among all the other groups at 24 h after IP administration (Figure 4.9C).
The treatment of mPAMD-TFTA/siRNA also showed the highest siRNA tumor-to-kidney
ratio (Figure 4.9D), and polymer tumor-to-liver ratio (Figure 4.9E) at 24 h, which
negatively correlates with siRNA premature release and polymer clearance by RES
respectively. HSA coating decreased the accumulation of both siRNA and polymer in
the tumors and all the other organs collected.
Nanoparticles are subject to clearance from the peritoneal cavity mainly by
lymphatic drainage [276, 280, 281]. Lipophilicity is one of the important determinants
for lymphatic transportation. As highly lipophilic drugs are prone to absorption into the
lymphatic system [280, 282, 283], the modification with TFTA which increases
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lipophobicity of the polymers and the nanoparticles could have contributed to the
slower peritoneal clearance of PAMD-TFTA/siRNA. The addition of HSA partly shielded
the surface TFTA moieties in the nanoparticles, which could result in their faster
clearance from the peritoneal cavity. On the other hand, PAMD-CHOL/siRNA
nanoparticles showed similar biodistribution pattern independent of HSA presence.
The impact of surface charge in the biodistribution of the nanoparticles by IP
administration seems to weigh less than that of the surface properties.

Figure 4.9. Biodistribution of the nanoparticles in orthotopic PDAC mice by IP injection.
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(A, B) Ex vivo fluorescence images of the tumors and major organs 4 h (A) and 24 h
(B) after IP administration captured by IVIS imaging system. Fluorescence intensity
was semi-quantified by IVIS software. SiRNA was labeled with Cy5.5 (Ex=675 nm,
Em=720 nm) and polymers were labeled with Cy3 (Ex=535 nm, Em=580 nm). (C)
Mean fluorescent intensity of Cy5.5-siRNA in primary tumors with different treatments
4 h and 24 h after IP administration. (D, E) Tumor/kidney Cy5.5-siRNA mean
fluorescent intensity ratio (D) and tumor/liver Cy3-polymer mean fluorescent intensity
ratio (E) of different treatments 4 h and 24 h after administration. Data are shown as
mean ± SD (n = 4). *P < 0.05, ***P < 0.001.

In addition to the effective accumulation in the primary tumor, we have observed
increased accumulation of the nanoparticles in the metastatic lesions in distant organs
(Figure 4.10). The metastatic lesions in the liver, spleen, and kidney showed much
higher uptake of both siRNA and mPAMD-TFTA than the surrounding healthy tissues.
As in the case of primary tumors, this may also be attributed to the lack of complete
mesothelial lining on the metastatic lesion surfaces. This pathophysiological feature
may contribute to limiting the off-target toxicity of the IP nanoparticles.

126

Figure 4.10. Biodistribution of the nanoparticle in metastatic tumors. Ex vivo
fluorescence images of biodistribution of mPAMD-TFTA/siRNA nanoparticles in the
metastatic tumors in liver, spleen, and kidney after IP injection.

Intratumoral distribution of the nanoparticles was evaluated by confocal
microscopy in frozen sections of the primary tumors. For the naked siRNA treatment,
the fluorescence signal was found only at the surface of the tumors. For the mPAMDTFTA/siRNA treated group, fluorescence of both siRNA and polymer was observed
concentrated at the tumor periphery and also reaching the center regions, suggesting
effective penetration ability (Figure 4.11). Similar results of tumor accumulation and
penetration after IP administration were also obtained in other studies with their
specific nanoparticles [237, 238, 279]. Mechanism of the tumor penetration ability of
our mPAMD-TFTA/siRNA nanoparticles is still not clear. Tumor associated
macrophages may participate in the transportation of the nanoparticles from the tumor
periphery into the center regions [284, 285]. Cell to cell transfer of the nanoparticles
might be another possible reason [238, 286].
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Figure 4.11. Intratumor distribution of the nanoparticles. (A) Confocal microscopy
images of frozen tumor sections treated with naked siRNA or mPAMD-TFTA/siRNA 24
h after IP injection. Scale bar = 200 μm. (B) Fluorescent images of whole tumor
sections treated with naked siRNA or mPAMD-TFTA/siRNA 24 h after IP injection.
Scale bar = 1000 μm. Cy5.5-siRNA was shown in green, Cy3-mPAMD-TFTA in red and
nuclei in blue (DAPI).

4.3.7. Therapeutic efficacy of IP delivered mPAMD-TFTA/siPLK1 nanoparticles
With mPAMD-TFTA/siRNA achieving a specific tumor accumulation and
penetration, further anti-tumor activity of the nanoparticles delivering siPLK1 was
studied in the KPC8060 orthotopic PDAC model. A combination effect of anti-CXCR4
and PLK1 downregulation was expected by IP administration of mPAMD-TFTA/siRNA

128

nanoparticles. Orthotopic PDAC mice were established as descried above. The
treatments were given every other day starting on day 14 post-implantation for a total
of 7 doses (Figure 4.12A). No gross toxicity of the nanoparticles was detected as there
were no significant body weight changes along the treatment journey (Figure 4.12B).
No obvious tissue toxicity was observed when examined the H&E staining slides of
major organs in different treatment groups by a pathologist (Figure 4.13). The tumor
volume was measured by ultrasound on day 12, 19 and 27 (Figure 4.12C). On day 27,
mPAMD-TFTA/siPLK1 treated group showed significantly smaller tumor volume
compared to the untreated (PBS) group. Tumor weight and metastasis frequency were
evaluated after animal sacrifice on day 28. A notable decrease in the tumor weight
(~40%) was achieved with the combined CXCR4 and PLK1 inhibition (Figure 4.12D).
CXCR4 inhibition alone (mPAMD-TFTA/siScr) also decreased the tumor volume and
weight to some extent. PLK1 mRNA levels in primary tumors were evaluated by RTPCR. A significant downregulation of PLK1 in the mPAMD-TFTA/siPLK1 treated group
(~22%) indicated successful delivery of the therapeutic RNA into the primary tumors
(Figure 4.12E).
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Figure 4.12. Therapeutic effect of the mPAMD-TFTA/siPLK1 nanoparticles in
orthotopic PDAC mice by IP administration. (A) Treatment scheme of the therapeutic
study. Tumor bearing mice were treated on day 14, 16, 18, 20, 22, 24 and 26 by IP
injection of PBS, mPAMD-TFTA/siScr or mPAMD-TFTA/siPLK1 nanoparticles (1.2
mg/kg siRNA, 6 mg/kg mPAMD-TFTA). (B) Relative mouse body weight (%) from
KPC8060 cell inoculation to scarification. (C) Tumor volumes of the mice with different
treatments on day 12, 19 and 27 measured by ultrasound and quantified by Vevo LAB
software. (D) Primary tumor weight and images in different treatment groups. Data are
shown as mean ± SD (n = 6). (E) Levels of PLK1 mRNA in tumors after treatments
analyzed by RT-PCR. Data are shown as mean ± SD (n = 5). *P < 0.05.
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Figure 4.13. H&E staining of major organs in different treatment groups. Scale bar =
200 μm.

With blocking of CXCR4/CXCL12 reported to have anti-metastatic activity in
multiple types of cancers [261, 287-289], we also investigated the inhibition of
metastasis of our nanoparticles. The orthotopic PDAC mice develop metastasis and
local invasion to multiple organs, including liver, spleen, kidney, intestine, diaphragm
and peritoneum (Figure 4.14A, B). Splenic invasion was observed for some of the mice
2 weeks after the KPC8060 cell implantation [180], which was before the start of the
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treatment. After mPAMD-TFTA/siScr nanoparticle treatment, the metastatic frequency
was reduced overall due to the inhibition of CXCR4 by the mPAMD-TFTA polymer,
especially in liver, intestine and diaphragm. However, the siPLK1 did not seem to add
additional anti-metastatic benefits in the broad range of examined organs.

Figure 4.14. Anti-metastatic effect of the mPAMD-TFTA/siPLK1 nanoparticles in
orthotropic KPC PDAC mice by IP administration. (A) Heat map of tumor metastasis
frequency in different organs and representative images in different treatment groups.
(B) Representative images of the major organs in each group. Black arrows indicate
metastatic tumors.

4.4 Conclusion
In summary, we have studied five different nanoparticle formulations with different
surface properties and charges that were able to inhibit CXCR4/CXCL12 signaling.
The modification with hydrophobic cholesterol and fluoroaryl moieties can facilitate the
cellular uptake and transfection efficacy of the nanoparticles, while modification of the
hydrophilic PEG hindered these activities.
The biodistribution of the nanoparticles by IP administration takes advantages of
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high concentrations directly at the tumor sites for longer period. The leaky mesothelium
at the tumor surfaces further promotes the tumor uptake of the nanoparticles. The
influence of surface coating with HSA seems to outweigh the surface charges of the
nanoparticles. Positively charged mPAMD-TFTA/siRNA nanoparticles had the most
significant tumor uptake of both siRNA and polymer among all the other groups 24 h
after injection as fluoroaryl modification was able to facilitate uptake and decrease
clearance by lymphatic system from the peritoneal cavity. Moreover, it displayed
markedly increased metastatic tumor uptake and tumor penetration ability, which
granted the following primary and metastatic tumor inhibition effect with combination
of anti-CXCR4 and PLK1 knockdown therapy.
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Chapter 5. Summary and future direction
5.1. Summary
Pancreatic cancer is an aggressive cancer type with increasing incidence and
death rate [8]. Early metastasis and late diagnosis lead to very limited options available
for the treatment of PDAC. Ineffectiveness of the conventional therapy is largely due
to the inability of drugs to reach the tumor sites owing to the inherent nature of dense
stroma and compressed blood vessels [71]. Novel effective therapies that are able to
target tumors, modulate the TME, and inhibit metastasis are in urgent need for the
treatment of PDAC.
In this dissertation, we developed dual-functional gene delivery vectors capable
of forming nanoparticles with small RNAs to simultaneously facilitate their delivery and
inhibition of CXCR4. Blockage of CXCR4/CXCL12 axis was proven effective in
inhibition of metastasis and increase of chemosensitivity [224, 290]. Therapeutic
siRNA or miRNA can regulate target mRNA expressions to suppress tumor progression.
With this combinational nanotherapy concept in mind, we first compared the
biodistribution of PAMD-CHOL/siRNA in orthotopic PDAC mice by IV or IP
administration. Compared with to a typical IV drug delivery, which would be hindered
by PDAC TME, locoregional IP delivery achieved specific tumor accumulation of the
nanoparticles taking advantage of high local drug concentration, longer peritoneal
retention, and leaky tumor mesothelial layers. Moreover, nanoparticles also
accumulated in metastatic tumors and penetrated into the tumor central regions.
Further therapeutic efficacy of the PAMD-CHOL nanoparticles delivering siKRASG12D
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and miR210 in orthotopic PDAC mice were studies. The triple combination therapy
was capable of reverse the tumor-suppressive microenvironment, inhibited both
primary and metastatic tumors and prolonged survival of the PDAC mice without any
obvious toxicity.
To explore what physiochemical properties of the nanoparticles can enhance
tumor accumulation and prolong peritoneal cavity retention, we developed five
nanoparticle formulations with different PAMD modifications (PEG, cholesterol and
fluorocarbon) and overall surface charges (neutral, positive and negative). The
hydrophilic PEG modified nanoparticles displayed instability with siRNA pre-release.
The hydrophobic cholesterol modified nanoparticles were relatively stable with highest
nanoparticle accumulation in tumors compared to other organs. The combined
hydrophobic and lipophobic fluorocarbon modification gave nanoparticles with minimal
siRNA release and extended period of IP retention. Positively charged mPAMDTFTA/siRNA nanoparticles displayed the most significant tumor uptake of both siRNA
and polymer among all the other groups 24 h after IP injection. Moreover, these
particles displayed markedly increased metastatic tumor uptake and tumor penetration
ability, which granted the following primary and metastatic tumor inhibition effect with
combination of anti-CXCR4 and PLK1 knockdown therapy.
Overall, we demonstrated the benefits of IP administration for the treatment of
PDAC and provided insights into the design of the nanoparticles for improved drug
delivery and combination therapy in PDAC by IP administration.
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5.2. Future directions
Despite the promising results found, we do not fully understand the mechanism
for the effective tumor penetration of our nanoparticles after IP administration. TAMs
were reported to be a possible reason for the transportation of nanoparticles from the
tumor periphery into the center regions [284, 285]. Wayne et al. demonstrated the
transient horizontal siRNA transfer into the cancer cells from the lipoplex-loaded
macrophages, possibly facilitated by Rb27a exosomal pathway [286]. We will examine
the mechanism by evaluating the trend of nanoparticle uptake by both macrophages
and cancer cells at different time points after IP administration with flow cytometry
analysis and tissue staining. We will also study the interaction between macrophages
and cancer cells and the isolated the exosomes released in the tumor to see if they
serve as the vehicles for nanoparticle transportation between cells.
As both PLK1 and CXCR4 overexpression are corelated with gemcitabine
resistance for the treatment of PDAC [291-293], our future studies will also include the
combination

of

gemcitabine

with

the

dual-functional

mPAMD-TFTA/siPLK1

nanoparticles to improve the anti-cancer and anti-metastatic effects in PDAC mice. We
can also use this dual-functional vector to delivery small RNAs aiming at other targets
for combination therapy. For example, as immunotherapy presents a promising
strategy for PDAC treatment, we can deliver siRNA targeting PD1/PD-L1 or CTLA-4
for enhanced checkpoint blockade, which has been reported to have synergistic effect
with CXCR4 antagonism [144, 294, 295]. In addition, we intend to further improve the
targeting and penetrating ability of the nanoparticles by introducing specific peptides,
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which can limit the off-target effects and expand the use of nanoparticles for bigger
tumors [296, 297].
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